Please wait while the formulary information is being retrieved.
Drug overview for NEUPOGEN (filgrastim):
Generic name: FILGRASTIM (fil-GRA-stim)
Drug class: Leukocyte Stimulating Factors
Therapeutic class: Hematological Agents
Filgrastim is a biosynthetic (recombinant DNA origin) hematopoietic agent (human granulocyte colony-stimulating factor (G-CSF)) that principally affects the proliferation and differentiation of neutrophils within the bone marrow and possibly other sites (e.g., spleen). Filgrastim and tbo-filgrastim are structurally and pharmacologically similar drugs that contain a related drug substance. Tbo-filgrastim was licensed by the US Food and Drug Administration (FDA) through a biologics license application (BLA), not as a biosimilar to filgrastim; at the time of tbo-filgrastim's submission for approval, FDA had not finalized a process for approving biosimilars.
Filgrastim-sndz, filgrastim-aafi, and filgrastim-ayow are biosimilar to filgrastim (Neupogen(R)). The FDA defines a biosimilar as a biological that is highly similar to an FDA-licensed reference biological with the exception of minor differences in clinically inactive components and for which there are no clinically meaningful differences in safety, purity, or potency. The claim of biosimilarity is based on a totality-of-evidence approach, which includes consideration of data from analytical, animal, and clinical studies (e.g., human pharmacokinetic and pharmacodynamic studies, clinical immunogenicity assessment, additional comparative clinical studies).
Therefore, biosimilarity of 2 drugs may be established even when there are formulation or minor structural differences or minor differences in rates of adverse effects between the drugs as long as these differences are not clinically meaningful. Biosimilars are approved through an abbreviated licensure pathway that establishes biosimilarity between the proposed biological and the reference biological but does not independently establish safety and effectiveness of the proposed biological. In order to be considered an interchangeable biosimilar, a biological product must meet additional requirements beyond demonstrating biosimilarity to its reference product; these requirements include demonstrating that the biological product can be expected to produce the same clinical results as the reference product in any given patient and, for a biological product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is no greater than the risk of using the reference product without such alternation or switch.
Biosimilar products that are interchangeable can be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference product. None of the currently available filgrastim biosimilars have interchangeable data at this time. In this monograph, unless otherwise stated, the term ''filgrastim products'' refers to filgastrim (the reference drug); tbo-filgrastim; filgrastim-sndz, filgrastim-aafi, and filgrastim-ayow (the biosimilars), or all products.
Various filgrastim biosimilars are available. Biosimilarity of these products has been demonstrated for the indications described in the table below (See Table 1.) Biosimilarity of the filgrastim products has not been demonstrated for use in patients with acute exposure to myelosuppressive doses of radiation; only the reference product (Neupogen(R)) is currently indicated for this use. Table 1.
Filgrastim Biosimilar Product and FDA-licensed Indications. FDA-labeled Filgrastim-sndz Filgrastim-aafi Filgrastim-ayow indication (Zarxio(R)) (Nivestym(R)) (Releuko(R)) Chemotherapy-indu X X X ced neutropenia Acute myeloid X X X leukemia Bone marrow X X X transplantation Autologous X X peripheral blood progenitor cell collection and therapy Severe chronic X X X neutropenia Tbo-filgrastim is only indicated for use in adult and pediatric patients (>=1 month of age) with non-myeloid malignancies receiving myelosuppressive chemotherapy associated with a significant incidence of febrile neutropenia in order to reduce the duration of severe neutropenia.
Generic name: FILGRASTIM (fil-GRA-stim)
Drug class: Leukocyte Stimulating Factors
Therapeutic class: Hematological Agents
Filgrastim is a biosynthetic (recombinant DNA origin) hematopoietic agent (human granulocyte colony-stimulating factor (G-CSF)) that principally affects the proliferation and differentiation of neutrophils within the bone marrow and possibly other sites (e.g., spleen). Filgrastim and tbo-filgrastim are structurally and pharmacologically similar drugs that contain a related drug substance. Tbo-filgrastim was licensed by the US Food and Drug Administration (FDA) through a biologics license application (BLA), not as a biosimilar to filgrastim; at the time of tbo-filgrastim's submission for approval, FDA had not finalized a process for approving biosimilars.
Filgrastim-sndz, filgrastim-aafi, and filgrastim-ayow are biosimilar to filgrastim (Neupogen(R)). The FDA defines a biosimilar as a biological that is highly similar to an FDA-licensed reference biological with the exception of minor differences in clinically inactive components and for which there are no clinically meaningful differences in safety, purity, or potency. The claim of biosimilarity is based on a totality-of-evidence approach, which includes consideration of data from analytical, animal, and clinical studies (e.g., human pharmacokinetic and pharmacodynamic studies, clinical immunogenicity assessment, additional comparative clinical studies).
Therefore, biosimilarity of 2 drugs may be established even when there are formulation or minor structural differences or minor differences in rates of adverse effects between the drugs as long as these differences are not clinically meaningful. Biosimilars are approved through an abbreviated licensure pathway that establishes biosimilarity between the proposed biological and the reference biological but does not independently establish safety and effectiveness of the proposed biological. In order to be considered an interchangeable biosimilar, a biological product must meet additional requirements beyond demonstrating biosimilarity to its reference product; these requirements include demonstrating that the biological product can be expected to produce the same clinical results as the reference product in any given patient and, for a biological product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is no greater than the risk of using the reference product without such alternation or switch.
Biosimilar products that are interchangeable can be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference product. None of the currently available filgrastim biosimilars have interchangeable data at this time. In this monograph, unless otherwise stated, the term ''filgrastim products'' refers to filgastrim (the reference drug); tbo-filgrastim; filgrastim-sndz, filgrastim-aafi, and filgrastim-ayow (the biosimilars), or all products.
Various filgrastim biosimilars are available. Biosimilarity of these products has been demonstrated for the indications described in the table below (See Table 1.) Biosimilarity of the filgrastim products has not been demonstrated for use in patients with acute exposure to myelosuppressive doses of radiation; only the reference product (Neupogen(R)) is currently indicated for this use. Table 1.
Filgrastim Biosimilar Product and FDA-licensed Indications. FDA-labeled Filgrastim-sndz Filgrastim-aafi Filgrastim-ayow indication (Zarxio(R)) (Nivestym(R)) (Releuko(R)) Chemotherapy-indu X X X ced neutropenia Acute myeloid X X X leukemia Bone marrow X X X transplantation Autologous X X peripheral blood progenitor cell collection and therapy Severe chronic X X X neutropenia Tbo-filgrastim is only indicated for use in adult and pediatric patients (>=1 month of age) with non-myeloid malignancies receiving myelosuppressive chemotherapy associated with a significant incidence of febrile neutropenia in order to reduce the duration of severe neutropenia.
DRUG IMAGES
NEUPOGEN 480 MCG/1.6 ML VIAL
NEUPOGEN 300 MCG/ML VIAL
NEUPOGEN 300 MCG/0.5 ML SYR
NEUPOGEN 480 MCG/0.8 ML SYR
The following indications for NEUPOGEN (filgrastim) have been approved by the FDA:
Indications:
Chemotherapy-induced neutropenia
Congenital neutropenia
Cyclic neutropenia
Hematopoietic syndrome of acute radiation syndrome
Idiopathic neutropenia
Neutropenia secondary to AML treatment
Peripheral mobilization of hematopoietic stem cells
Prevention of neutropenia from cancer chemotherapy
Severe chronic neutropenia
Professional Synonyms:
Bone marrow syndrome of acute radiation syndrome
Congenital aleukia
Congenital leukopenia
Infantile genetic agranulocytosis
Kostmann neutropenia
Kostmann syndrome
Neutropenia due to acute myelocytic leukemia treatment
Neutropenia of unknown origin
Neutrophilic leukocytopenia from cancer chemotherapy
Neutrophilic leukopenia from cancer chemotherapy
Neutrophilopenia from cancer chemotherapy
Patient with acute exposure to myelosuppressive dose of radiation
Periodic neutropenia
Primary neutropenia
Indications:
Chemotherapy-induced neutropenia
Congenital neutropenia
Cyclic neutropenia
Hematopoietic syndrome of acute radiation syndrome
Idiopathic neutropenia
Neutropenia secondary to AML treatment
Peripheral mobilization of hematopoietic stem cells
Prevention of neutropenia from cancer chemotherapy
Severe chronic neutropenia
Professional Synonyms:
Bone marrow syndrome of acute radiation syndrome
Congenital aleukia
Congenital leukopenia
Infantile genetic agranulocytosis
Kostmann neutropenia
Kostmann syndrome
Neutropenia due to acute myelocytic leukemia treatment
Neutropenia of unknown origin
Neutrophilic leukocytopenia from cancer chemotherapy
Neutrophilic leukopenia from cancer chemotherapy
Neutrophilopenia from cancer chemotherapy
Patient with acute exposure to myelosuppressive dose of radiation
Periodic neutropenia
Primary neutropenia
The following dosing information is available for NEUPOGEN (filgrastim):
The reference filgrastim product (Neupogen(R)) is used to improve survival in patients acutely exposed to myelosuppressive radiation doses.
The recommended subcutaneous dosage of filgrastim (Neupogen(R)) is 10 mcg/kg as a single daily subcutaneous injection. Give the dose as soon as possible after suspected or confirmed exposure to radiation doses >2 gray. Continue therapy until the ANC is >1000 cells/mm3 for 3 consecutive CBCs or exceeds 10,000 cells/mm3 after a radiation-induced nadir.
Obtain a baseline CBC and subsequent serial CBCs approximately every third day until the ANC is >1000 cells/mm3 for 3 consecutive CBCs. Do not delay therapy if a CBC is not readily available.
Estimate the level of radiation exposure via clinical findings (e.g., time to vomiting onset, lymphocyte depletion kinetics), biodosimetry (if available), and information from public health authorities.
The recommended subcutaneous dosage of filgrastim (Neupogen(R)) is 10 mcg/kg as a single daily subcutaneous injection. Give the dose as soon as possible after suspected or confirmed exposure to radiation doses >2 gray. Continue therapy until the ANC is >1000 cells/mm3 for 3 consecutive CBCs or exceeds 10,000 cells/mm3 after a radiation-induced nadir.
Obtain a baseline CBC and subsequent serial CBCs approximately every third day until the ANC is >1000 cells/mm3 for 3 consecutive CBCs. Do not delay therapy if a CBC is not readily available.
Estimate the level of radiation exposure via clinical findings (e.g., time to vomiting onset, lymphocyte depletion kinetics), biodosimetry (if available), and information from public health authorities.
Depending on the product and indication for use, filgrastim may be administered by subcutaneous injection, short IV infusion (15 to 30 minutes), or continuous IV infusion. Filgrastim has also been administered by continuous subcutaneous infusion+. When administered by continuous subcutaneous infusion for chemotherapy-induced neutropenia or bone marrow transplantation (BMT), filgrastim has been infused over 24 hours.
For extended IV or subcutaneous infusions, a controlled-infusion device generally is employed. Subcutaneous injection is the most convenient for self-administration of the filgrastim products and is especially useful when prolonged maintenance therapy with the drug is necessary. Recommended sites for subcutaneous injection of filgrastim, tbo-filgrastim, or biosimilars include the outer area of the upper arms, abdomen (except for the 2-inch area around the navel), thighs, and the upper outer areas of the buttocks.
Injection sites should be rotated daily; any area that is tender, red, bruised, scaly, hard, or has stretch marks or scars should be avoided. If a filgrastim product is administered by a patient or caregiver and a dose is missed, the patient or caregiver should contact their healthcare provider. Discard any unused portion of filgastrim product in vials or prefilled syringes.
Do not re-enter the vial and do not save unused filgrastim product for administration at a later date. Visually inspect any filgrastim products for particulate matter and discoloration prior to administration. Do not administer filgrastim products if particulate matter or discoloration is observed.
Avoid shaking filgrastim products. Transport of filgrastim via a pneumatic tube system has not been evaluated.
For extended IV or subcutaneous infusions, a controlled-infusion device generally is employed. Subcutaneous injection is the most convenient for self-administration of the filgrastim products and is especially useful when prolonged maintenance therapy with the drug is necessary. Recommended sites for subcutaneous injection of filgrastim, tbo-filgrastim, or biosimilars include the outer area of the upper arms, abdomen (except for the 2-inch area around the navel), thighs, and the upper outer areas of the buttocks.
Injection sites should be rotated daily; any area that is tender, red, bruised, scaly, hard, or has stretch marks or scars should be avoided. If a filgrastim product is administered by a patient or caregiver and a dose is missed, the patient or caregiver should contact their healthcare provider. Discard any unused portion of filgastrim product in vials or prefilled syringes.
Do not re-enter the vial and do not save unused filgrastim product for administration at a later date. Visually inspect any filgrastim products for particulate matter and discoloration prior to administration. Do not administer filgrastim products if particulate matter or discoloration is observed.
Avoid shaking filgrastim products. Transport of filgrastim via a pneumatic tube system has not been evaluated.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| NEUPOGEN 480 MCG/0.8 ML SYR | Maintenance | Adults inject 5 mcg/kg by subcutaneous route once daily |
| NEUPOGEN 300 MCG/ML VIAL | Maintenance | Adults inject 5 mcg/kg by subcutaneous route once daily |
| NEUPOGEN 480 MCG/1.6 ML VIAL | Maintenance | Adults inject 5 mcg/kg by subcutaneous route once daily |
| NEUPOGEN 300 MCG/0.5 ML SYR | Maintenance | Adults inject 5 mcg/kg by subcutaneous route once daily |
No generic dosing information available.
The following drug interaction information is available for NEUPOGEN (filgrastim):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for NEUPOGEN (filgrastim):
Drug contraindication overview.
*History of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.
*History of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.
There are 0 contraindications.
There are 6 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Acute respiratory distress syndrome |
| Alveolar hemorrhage |
| Glomerulonephritis |
| Leukocytosis |
| Nontraumatic splenic rupture |
| Sickle cell disease |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Cutaneous vasculitis |
The following adverse reaction information is available for NEUPOGEN (filgrastim):
Adverse reaction overview.
The most common (>=5% difference in incidence as compared to placebo) adverse reactions in patients with nonmyeloid malignancies administered myelosuppressive chemotherapy receiving filgrastim and biosimilars include pyrexia, pain, rash, cough, and dyspnea. The most common (>=2% difference in incidence as compared to placebo) adverse reactions in patients with AML receiving filgrastim and biosimilars include pain, epistaxis, and rash. The most common (>=5% difference in incidence as compared to placebo) adverse reaction in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by BMT receiving filgrastim and biosimilars includes rash.
The most common (>=5%) adverse reactions in patients undergoing PBPC mobilization and collection receiving filgrastim and biosimilars include bone pain, pyrexia, and headache. The most common (>=5% difference in incidence as compared to placebo) adverse reactions in patients with severe chronic neutropenia receiving filgrastim and biosimilars include pain, anemia, epistaxis, diarrhea, hypoesthesia, and alopecia. The most common (>=1%) adverse reaction for patients administered tbo-filgrastim is bone pain.
The most common (>=5% difference in incidence as compared to placebo) adverse reactions in patients with nonmyeloid malignancies administered myelosuppressive chemotherapy receiving filgrastim and biosimilars include pyrexia, pain, rash, cough, and dyspnea. The most common (>=2% difference in incidence as compared to placebo) adverse reactions in patients with AML receiving filgrastim and biosimilars include pain, epistaxis, and rash. The most common (>=5% difference in incidence as compared to placebo) adverse reaction in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by BMT receiving filgrastim and biosimilars includes rash.
The most common (>=5%) adverse reactions in patients undergoing PBPC mobilization and collection receiving filgrastim and biosimilars include bone pain, pyrexia, and headache. The most common (>=5% difference in incidence as compared to placebo) adverse reactions in patients with severe chronic neutropenia receiving filgrastim and biosimilars include pain, anemia, epistaxis, diarrhea, hypoesthesia, and alopecia. The most common (>=1%) adverse reaction for patients administered tbo-filgrastim is bone pain.
There are 21 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Hypertension Injection site sequelae Leukocytosis Peritonitis |
| Rare/Very Rare |
|---|
|
Acute respiratory distress syndrome Alveolar hemorrhage Anaphylaxis Aortitis Capillary leak syndrome Cutaneous vasculitis Extramedullary hematopoietic mass Glomerulonephritis Hemoptysis Hepatomegaly Nontraumatic splenic rupture Osteoporosis Pulmonary hemorrhage Splenomegaly Supraventricular arrhythmias Sweet's syndrome Thrombocytopenic disorder |
There are 29 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Arthralgia Bone pain Cough Fatigue Fever Headache disorder Hypoesthesia Myalgia Nausea Pain Pruritus of skin Skin rash Vomiting |
Back pain Dyspnea Epistaxis Erythema Maculopapular rash Pain in extremities Petechiae |
| Rare/Very Rare |
|---|
|
Alopecia Chest pain Diarrhea Drug-exacerbated psoriasis General weakness Hematuria Proteinuria Upper respiratory infection Urinary tract infection |
The following precautions are available for NEUPOGEN (filgrastim):
In a study of patients with cancer administered myelosuppressive chemotherapy, 15 pediatric patients (median age: 2.6 years; range, 1.2 to 9.4 years) were included and administered filgrastim doses of 5, 10, or 15 mcg/kg/day for 10 days. The pharmacokinetics of filgrastim in pediatric patients after chemotherapy administration are comparable to those seen in adults administered the same weight-normalized doses. Filgrastim is also well tolerated in pediatric patients receiving myelosuppressive chemotherapy, with the only consistently reported adverse event being musculoskeletal pain.
The effectiveness and safety of filgrastim in pediatric patients with severe chronic neutropenia have also been established in a phase 3 study. In this study, 123 patients (median age: 12 years; range, 7 months to 76 years) were evaluated including 12 infants, 49 children, and 9 adolescents. Additionally, a postmarketing surveillance study included 429 pediatric patients (<18 years of age; range: 0.9 to 17 years) of 731 total patients with severe chronic neutropenia.
Results from this long-term surveillance study suggest that height and weight are not adversely affected in patients who were administered up to 5 years of filgrastim therapy. Limited data from the phase 3 study did not suggest alterations in sexual maturation or endocrine function as well in patients who were followed for 1.5 years.
The development of cytogenetic abnormalities and transformation to MDS and AML have occurred in pediatric patients with congenital types of neutropenia administered long-term filgrastim. Any relationship between filgrastim administration and the development of these adverse events is unknown. The administration of filgrastim to increase survival in pediatric patients acutely exposed to myelosuppressive radiation doses is based on results from animal studies and clinical data supporting the use of filgrastim in other indications.
Tbo-filgrastim is indicated for use in pediatric patients at least 1 month old with non-myeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia, in order to reduce the duration of severe neutropenia. This indication is based on evidence from studies in adults and additional safety and pharmacokinetics data from a single-arm trial of 50 pediatric patients (median age: 9.2 years; range: 1.4 to 15.9 years) with solid tumors administered tbo-filgrastim. Overall, the pharmacokinetics and safety profile of tbo-filgrastim in the pediatric population were similar to that observed in an adult population.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
The effectiveness and safety of filgrastim in pediatric patients with severe chronic neutropenia have also been established in a phase 3 study. In this study, 123 patients (median age: 12 years; range, 7 months to 76 years) were evaluated including 12 infants, 49 children, and 9 adolescents. Additionally, a postmarketing surveillance study included 429 pediatric patients (<18 years of age; range: 0.9 to 17 years) of 731 total patients with severe chronic neutropenia.
Results from this long-term surveillance study suggest that height and weight are not adversely affected in patients who were administered up to 5 years of filgrastim therapy. Limited data from the phase 3 study did not suggest alterations in sexual maturation or endocrine function as well in patients who were followed for 1.5 years.
The development of cytogenetic abnormalities and transformation to MDS and AML have occurred in pediatric patients with congenital types of neutropenia administered long-term filgrastim. Any relationship between filgrastim administration and the development of these adverse events is unknown. The administration of filgrastim to increase survival in pediatric patients acutely exposed to myelosuppressive radiation doses is based on results from animal studies and clinical data supporting the use of filgrastim in other indications.
Tbo-filgrastim is indicated for use in pediatric patients at least 1 month old with non-myeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia, in order to reduce the duration of severe neutropenia. This indication is based on evidence from studies in adults and additional safety and pharmacokinetics data from a single-arm trial of 50 pediatric patients (median age: 9.2 years; range: 1.4 to 15.9 years) with solid tumors administered tbo-filgrastim. Overall, the pharmacokinetics and safety profile of tbo-filgrastim in the pediatric population were similar to that observed in an adult population.
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Clinical data have not established a link between filgrastim use during pregnancy and the occurrence of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Published reports have described transplacental movement of filgrastim in pregnant women when given <=30 hours prior to preterm delivery (<=30 weeks gestation). In pregnant rats, no maternal or fetal effects were observed at filgrastim doses up to 58 times the human dose.
Adverse effects were noted in pregnant rabbits with filgrastim doses 2 to 10 times higher than the human dose. No malformations were reported in the offspring of pregnant rats or rabbits given filgrastim. Administration of tbo-filgrastim to pregnant rabbits during organogenesis resulted in increased spontaneous abortion and fetal malformations at systemic exposures 50-90 times the human exposure expected at the recommended human dose. Tbo-filgrastim should be used during pregnancy only if the potential benefit justifies the potential fetal risk.
Adverse effects were noted in pregnant rabbits with filgrastim doses 2 to 10 times higher than the human dose. No malformations were reported in the offspring of pregnant rats or rabbits given filgrastim. Administration of tbo-filgrastim to pregnant rabbits during organogenesis resulted in increased spontaneous abortion and fetal malformations at systemic exposures 50-90 times the human exposure expected at the recommended human dose. Tbo-filgrastim should be used during pregnancy only if the potential benefit justifies the potential fetal risk.
Case reports exist describing the use of filgrastim in breast-feeding mothers; no adverse effects were observed in exposed infants. No data exist regarding the effects of filgrastim on milk production. Filgrastim is excreted poorly in breastmilk and is not absorbed orally by neonates.
Consider the benefits of breast-feeding along with the mother's need for filgrastim against any potential adverse effects on the breast-feeding infant from filgrastim therapy or the underlying maternal condition. No data are available regarding the presence of tbo-filgrastim in breastmilk, effects on the breastfed child, or effects on milk production.
Consider the benefits of breast-feeding along with the mother's need for filgrastim against any potential adverse effects on the breast-feeding infant from filgrastim therapy or the underlying maternal condition. No data are available regarding the presence of tbo-filgrastim in breastmilk, effects on the breastfed child, or effects on milk production.
In clinical studies of filgrastim-treated patients administered myelosuppressive chemotherapy involving 855 patients, 232 patients were >=65 years of age and 22 were >=75 years of age. There were no differences in effectiveness or safety observed between these patients and younger patients. In clinical studies of filgrastim-treated patients for other approved indications, there were insufficient numbers of patients >=65 years of age to determine whether these patients responded differently than younger patients.
In clinical studies of tbo-filgrastim, 111 patients were >=65 years of age and 14 patients were >=75 years of age. There were no differences in effectiveness or safety observed between patients >=65 years of age and younger patients.
In clinical studies of tbo-filgrastim, 111 patients were >=65 years of age and 14 patients were >=75 years of age. There were no differences in effectiveness or safety observed between patients >=65 years of age and younger patients.
The following prioritized warning is available for NEUPOGEN (filgrastim):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for NEUPOGEN (filgrastim)'s list of indications:
| Chemotherapy-induced neutropenia | |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| Congenital neutropenia | |
| D70.0 | Congenital agranulocytosis |
| Cyclic neutropenia | |
| D70.4 | Cyclic neutropenia |
| Hematopoietic syndrome of acute radiation syndrome | |
| T66.xxxA | Radiation sickness, unspecified, initial encounter |
| T66.xxxD | Radiation sickness, unspecified, subsequent encounter |
| Idiopathic neutropenia | |
| D70 | Neutropenia |
| D70.8 | Other neutropenia |
| D70.9 | Neutropenia, unspecified |
| Neutropenia secondary to AML treatment | |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| Peripheral mobilization of hematopoietic stem cells | |
| Z52.011 | Autologous donor, stem cells |
| Prevention of neutropenia from cancer chemotherapy | |
| C00 | Malignant neoplasm of lip |
| C00.0 | Malignant neoplasm of external upper lip |
| C00.1 | Malignant neoplasm of external lower lip |
| C00.2 | Malignant neoplasm of external lip, unspecified |
| C00.3 | Malignant neoplasm of upper lip, inner aspect |
| C00.4 | Malignant neoplasm of lower lip, inner aspect |
| C00.5 | Malignant neoplasm of lip, unspecified, inner aspect |
| C00.6 | Malignant neoplasm of commissure of lip, unspecified |
| C00.8 | Malignant neoplasm of overlapping sites of lip |
| C00.9 | Malignant neoplasm of lip, unspecified |
| C01 | Malignant neoplasm of base of tongue |
| C02 | Malignant neoplasm of other and unspecified parts of tongue |
| C02.0 | Malignant neoplasm of dorsal surface of tongue |
| C02.1 | Malignant neoplasm of border of tongue |
| C02.2 | Malignant neoplasm of ventral surface of tongue |
| C02.3 | Malignant neoplasm of anterior two-thirds of tongue, part unspecified |
| C02.4 | Malignant neoplasm of lingual tonsil |
| C02.8 | Malignant neoplasm of overlapping sites of tongue |
| C02.9 | Malignant neoplasm of tongue, unspecified |
| C03 | Malignant neoplasm of gum |
| C03.0 | Malignant neoplasm of upper gum |
| C03.1 | Malignant neoplasm of lower gum |
| C03.9 | Malignant neoplasm of gum, unspecified |
| C04 | Malignant neoplasm of floor of mouth |
| C04.0 | Malignant neoplasm of anterior floor of mouth |
| C04.1 | Malignant neoplasm of lateral floor of mouth |
| C04.8 | Malignant neoplasm of overlapping sites of floor of mouth |
| C04.9 | Malignant neoplasm of floor of mouth, unspecified |
| C05 | Malignant neoplasm of palate |
| C05.0 | Malignant neoplasm of hard palate |
| C05.1 | Malignant neoplasm of soft palate |
| C05.2 | Malignant neoplasm of uvula |
| C05.8 | Malignant neoplasm of overlapping sites of palate |
| C05.9 | Malignant neoplasm of palate, unspecified |
| C06 | Malignant neoplasm of other and unspecified parts of mouth |
| C06.0 | Malignant neoplasm of cheek mucosa |
| C06.1 | Malignant neoplasm of vestibule of mouth |
| C06.2 | Malignant neoplasm of retromolar area |
| C06.8 | Malignant neoplasm of overlapping sites of other and unspecified parts of mouth |
| C06.80 | Malignant neoplasm of overlapping sites of unspecified parts of mouth |
| C06.89 | Malignant neoplasm of overlapping sites of other parts of mouth |
| C06.9 | Malignant neoplasm of mouth, unspecified |
| C07 | Malignant neoplasm of parotid gland |
| C08 | Malignant neoplasm of other and unspecified major salivary glands |
| C08.0 | Malignant neoplasm of submandibular gland |
| C08.1 | Malignant neoplasm of sublingual gland |
| C08.9 | Malignant neoplasm of major salivary gland, unspecified |
| C09 | Malignant neoplasm of tonsil |
| C09.0 | Malignant neoplasm of tonsillar fossa |
| C09.1 | Malignant neoplasm of tonsillar pillar (anterior) (posterior) |
| C09.8 | Malignant neoplasm of overlapping sites of tonsil |
| C09.9 | Malignant neoplasm of tonsil, unspecified |
| C10 | Malignant neoplasm of oropharynx |
| C10.0 | Malignant neoplasm of vallecula |
| C10.1 | Malignant neoplasm of anterior surface of epiglottis |
| C10.2 | Malignant neoplasm of lateral wall of oropharynx |
| C10.3 | Malignant neoplasm of posterior wall of oropharynx |
| C10.4 | Malignant neoplasm of branchial cleft |
| C10.8 | Malignant neoplasm of overlapping sites of oropharynx |
| C10.9 | Malignant neoplasm of oropharynx, unspecified |
| C11 | Malignant neoplasm of nasopharynx |
| C11.0 | Malignant neoplasm of superior wall of nasopharynx |
| C11.1 | Malignant neoplasm of posterior wall of nasopharynx |
| C11.2 | Malignant neoplasm of lateral wall of nasopharynx |
| C11.3 | Malignant neoplasm of anterior wall of nasopharynx |
| C11.8 | Malignant neoplasm of overlapping sites of nasopharynx |
| C11.9 | Malignant neoplasm of nasopharynx, unspecified |
| C12 | Malignant neoplasm of pyriform sinus |
| C13 | Malignant neoplasm of hypopharynx |
| C13.0 | Malignant neoplasm of postcricoid region |
| C13.1 | Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect |
| C13.2 | Malignant neoplasm of posterior wall of hypopharynx |
| C13.8 | Malignant neoplasm of overlapping sites of hypopharynx |
| C13.9 | Malignant neoplasm of hypopharynx, unspecified |
| C14 | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx |
| C14.0 | Malignant neoplasm of pharynx, unspecified |
| C14.2 | Malignant neoplasm of waldeyer's ring |
| C14.8 | Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx |
| C15 | Malignant neoplasm of esophagus |
| C15.3 | Malignant neoplasm of upper third of esophagus |
| C15.4 | Malignant neoplasm of middle third of esophagus |
| C15.5 | Malignant neoplasm of lower third of esophagus |
| C15.8 | Malignant neoplasm of overlapping sites of esophagus |
| C15.9 | Malignant neoplasm of esophagus, unspecified |
| C16 | Malignant neoplasm of stomach |
| C16.0 | Malignant neoplasm of cardia |
| C16.1 | Malignant neoplasm of fundus of stomach |
| C16.2 | Malignant neoplasm of body of stomach |
| C16.3 | Malignant neoplasm of pyloric antrum |
| C16.4 | Malignant neoplasm of pylorus |
| C16.5 | Malignant neoplasm of lesser curvature of stomach, unspecified |
| C16.6 | Malignant neoplasm of greater curvature of stomach, unspecified |
| C16.8 | Malignant neoplasm of overlapping sites of stomach |
| C16.9 | Malignant neoplasm of stomach, unspecified |
| C17 | Malignant neoplasm of small intestine |
| C17.0 | Malignant neoplasm of duodenum |
| C17.1 | Malignant neoplasm of jejunum |
| C17.2 | Malignant neoplasm of ileum |
| C17.3 | Meckel's diverticulum, malignant |
| C17.8 | Malignant neoplasm of overlapping sites of small intestine |
| C17.9 | Malignant neoplasm of small intestine, unspecified |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21 | Malignant neoplasm of anus and anal canal |
| C21.0 | Malignant neoplasm of anus, unspecified |
| C21.1 | Malignant neoplasm of anal canal |
| C21.2 | Malignant neoplasm of cloacogenic zone |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| C22 | Malignant neoplasm of liver and intrahepatic bile ducts |
| C22.0 | Liver cell carcinoma |
| C22.1 | Intrahepatic bile duct carcinoma |
| C22.2 | Hepatoblastoma |
| C22.3 | Angiosarcoma of liver |
| C22.4 | Other sarcomas of liver |
| C22.7 | Other specified carcinomas of liver |
| C22.8 | Malignant neoplasm of liver, primary, unspecified as to type |
| C22.9 | Malignant neoplasm of liver, not specified as primary or secondary |
| C23 | Malignant neoplasm of gallbladder |
| C24 | Malignant neoplasm of other and unspecified parts of biliary tract |
| C24.0 | Malignant neoplasm of extrahepatic bile duct |
| C24.1 | Malignant neoplasm of ampulla of vater |
| C24.8 | Malignant neoplasm of overlapping sites of biliary tract |
| C24.9 | Malignant neoplasm of biliary tract, unspecified |
| C25 | Malignant neoplasm of pancreas |
| C25.0 | Malignant neoplasm of head of pancreas |
| C25.1 | Malignant neoplasm of body of pancreas |
| C25.2 | Malignant neoplasm of tail of pancreas |
| C25.3 | Malignant neoplasm of pancreatic duct |
| C25.4 | Malignant neoplasm of endocrine pancreas |
| C25.7 | Malignant neoplasm of other parts of pancreas |
| C25.8 | Malignant neoplasm of overlapping sites of pancreas |
| C25.9 | Malignant neoplasm of pancreas, unspecified |
| C26 | Malignant neoplasm of other and ill-defined digestive organs |
| C26.0 | Malignant neoplasm of intestinal tract, part unspecified |
| C26.1 | Malignant neoplasm of spleen |
| C26.9 | Malignant neoplasm of ill-defined sites within the digestive system |
| C30 | Malignant neoplasm of nasal cavity and middle ear |
| C30.0 | Malignant neoplasm of nasal cavity |
| C30.1 | Malignant neoplasm of middle ear |
| C31 | Malignant neoplasm of accessory sinuses |
| C31.0 | Malignant neoplasm of maxillary sinus |
| C31.1 | Malignant neoplasm of ethmoidal sinus |
| C31.2 | Malignant neoplasm of frontal sinus |
| C31.3 | Malignant neoplasm of sphenoid sinus |
| C31.8 | Malignant neoplasm of overlapping sites of accessory sinuses |
| C31.9 | Malignant neoplasm of accessory sinus, unspecified |
| C32 | Malignant neoplasm of larynx |
| C32.0 | Malignant neoplasm of glottis |
| C32.1 | Malignant neoplasm of supraglottis |
| C32.2 | Malignant neoplasm of subglottis |
| C32.3 | Malignant neoplasm of laryngeal cartilage |
| C32.8 | Malignant neoplasm of overlapping sites of larynx |
| C32.9 | Malignant neoplasm of larynx, unspecified |
| C33 | Malignant neoplasm of trachea |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C37 | Malignant neoplasm of thymus |
| C38 | Malignant neoplasm of heart, mediastinum and pleura |
| C38.0 | Malignant neoplasm of heart |
| C38.1 | Malignant neoplasm of anterior mediastinum |
| C38.2 | Malignant neoplasm of posterior mediastinum |
| C38.3 | Malignant neoplasm of mediastinum, part unspecified |
| C38.4 | Malignant neoplasm of pleura |
| C38.8 | Malignant neoplasm of overlapping sites of heart, mediastinum and pleura |
| C39 | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs |
| C39.0 | Malignant neoplasm of upper respiratory tract, part unspecified |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| C40 | Malignant neoplasm of bone and articular cartilage of limbs |
| C40.0 | Malignant neoplasm of scapula and long bones of upper limb |
| C40.00 | Malignant neoplasm of scapula and long bones of unspecified upper limb |
| C40.01 | Malignant neoplasm of scapula and long bones of right upper limb |
| C40.02 | Malignant neoplasm of scapula and long bones of left upper limb |
| C40.1 | Malignant neoplasm of short bones of upper limb |
| C40.10 | Malignant neoplasm of short bones of unspecified upper limb |
| C40.11 | Malignant neoplasm of short bones of right upper limb |
| C40.12 | Malignant neoplasm of short bones of left upper limb |
| C40.2 | Malignant neoplasm of long bones of lower limb |
| C40.20 | Malignant neoplasm of long bones of unspecified lower limb |
| C40.21 | Malignant neoplasm of long bones of right lower limb |
| C40.22 | Malignant neoplasm of long bones of left lower limb |
| C40.3 | Malignant neoplasm of short bones of lower limb |
| C40.30 | Malignant neoplasm of short bones of unspecified lower limb |
| C40.31 | Malignant neoplasm of short bones of right lower limb |
| C40.32 | Malignant neoplasm of short bones of left lower limb |
| C40.8 | Malignant neoplasm of overlapping sites of bone and articular cartilage of limb |
| C40.80 | Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb |
| C40.81 | Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb |
| C40.82 | Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb |
| C40.9 | Malignant neoplasm of unspecified bones and articular cartilage of limb |
| C40.90 | Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb |
| C40.91 | Malignant neoplasm of unspecified bones and articular cartilage of right limb |
| C40.92 | Malignant neoplasm of unspecified bones and articular cartilage of left limb |
| C41 | Malignant neoplasm of bone and articular cartilage of other and unspecified sites |
| C41.0 | Malignant neoplasm of bones of skull and face |
| C41.1 | Malignant neoplasm of mandible |
| C41.2 | Malignant neoplasm of vertebral column |
| C41.3 | Malignant neoplasm of ribs, sternum and clavicle |
| C41.4 | Malignant neoplasm of pelvic bones, sacrum and coccyx |
| C41.9 | Malignant neoplasm of bone and articular cartilage, unspecified |
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
| C44 | Other and unspecified malignant neoplasm of skin |
| C44.0 | Other and unspecified malignant neoplasm of skin of lip |
| C44.00 | Unspecified malignant neoplasm of skin of lip |
| C44.01 | Basal cell carcinoma of skin of lip |
| C44.02 | Squamous cell carcinoma of skin of lip |
| C44.09 | Other specified malignant neoplasm of skin of lip |
| C44.1 | Other and unspecified malignant neoplasm of skin of eyelid, including canthus |
| C44.10 | Unspecified malignant neoplasm of skin of eyelid, including canthus |
| C44.101 | Unspecified malignant neoplasm of skin of unspecified eyelid, including canthus |
| C44.102 | Unspecified malignant neoplasm of skin of right eyelid, including canthus |
| C44.1021 | Unspecified malignant neoplasm of skin of right upper eyelid, including canthus |
| C44.1022 | Unspecified malignant neoplasm of skin of right lower eyelid, including canthus |
| C44.109 | Unspecified malignant neoplasm of skin of left eyelid, including canthus |
| C44.1091 | Unspecified malignant neoplasm of skin of left upper eyelid, including canthus |
| C44.1092 | Unspecified malignant neoplasm of skin of left lower eyelid, including canthus |
| C44.11 | Basal cell carcinoma of skin of eyelid, including canthus |
| C44.111 | Basal cell carcinoma of skin of unspecified eyelid, including canthus |
| C44.112 | Basal cell carcinoma of skin of right eyelid, including canthus |
| C44.1121 | Basal cell carcinoma of skin of right upper eyelid, including canthus |
| C44.1122 | Basal cell carcinoma of skin of right lower eyelid, including canthus |
| C44.119 | Basal cell carcinoma of skin of left eyelid, including canthus |
| C44.1191 | Basal cell carcinoma of skin of left upper eyelid, including canthus |
| C44.1192 | Basal cell carcinoma of skin of left lower eyelid, including canthus |
| C44.12 | Squamous cell carcinoma of skin of eyelid, including canthus |
| C44.121 | Squamous cell carcinoma of skin of unspecified eyelid, including canthus |
| C44.122 | Squamous cell carcinoma of skin of right eyelid, including canthus |
| C44.1221 | Squamous cell carcinoma of skin of right upper eyelid, including canthus |
| C44.1222 | Squamous cell carcinoma of skin of right lower eyelid, including canthus |
| C44.129 | Squamous cell carcinoma of skin of left eyelid, including canthus |
| C44.1291 | Squamous cell carcinoma of skin of left upper eyelid, including canthus |
| C44.1292 | Squamous cell carcinoma of skin of left lower eyelid, including canthus |
| C44.13 | Sebaceous cell carcinoma of skin of eyelid, including canthus |
| C44.131 | Sebaceous cell carcinoma of skin of unspecified eyelid, including canthus |
| C44.132 | Sebaceous cell carcinoma of skin of right eyelid, including canthus |
| C44.1321 | Sebaceous cell carcinoma of skin of right upper eyelid, including canthus |
| C44.1322 | Sebaceous cell carcinoma of skin of right lower eyelid, including canthus |
| C44.139 | Sebaceous cell carcinoma of skin of left eyelid, including canthus |
| C44.1391 | Sebaceous cell carcinoma of skin of left upper eyelid, including canthus |
| C44.1392 | Sebaceous cell carcinoma of skin of left lower eyelid, including canthus |
| C44.19 | Other specified malignant neoplasm of skin of eyelid, including canthus |
| C44.191 | Other specified malignant neoplasm of skin of unspecified eyelid, including canthus |
| C44.192 | Other specified malignant neoplasm of skin of right eyelid, including canthus |
| C44.1921 | Other specified malignant neoplasm of skin of right upper eyelid, including canthus |
| C44.1922 | Other specified malignant neoplasm of skin of right lower eyelid, including canthus |
| C44.199 | Other specified malignant neoplasm of skin of left eyelid, including canthus |
| C44.1991 | Other specified malignant neoplasm of skin of left upper eyelid, including canthus |
| C44.1992 | Other specified malignant neoplasm of skin of left lower eyelid, including canthus |
| C44.2 | Other and unspecified malignant neoplasm of skin of ear and external auricular canal |
| C44.20 | Unspecified malignant neoplasm of skin of ear and external auricular canal |
| C44.201 | Unspecified malignant neoplasm of skin of unspecified ear and external auricular canal |
| C44.202 | Unspecified malignant neoplasm of skin of right ear and external auricular canal |
| C44.209 | Unspecified malignant neoplasm of skin of left ear and external auricular canal |
| C44.21 | Basal cell carcinoma of skin of ear and external auricular canal |
| C44.211 | Basal cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.212 | Basal cell carcinoma of skin of right ear and external auricular canal |
| C44.219 | Basal cell carcinoma of skin of left ear and external auricular canal |
| C44.22 | Squamous cell carcinoma of skin of ear and external auricular canal |
| C44.221 | Squamous cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.222 | Squamous cell carcinoma of skin of right ear and external auricular canal |
| C44.229 | Squamous cell carcinoma of skin of left ear and external auricular canal |
| C44.29 | Other specified malignant neoplasm of skin of ear and external auricular canal |
| C44.291 | Other specified malignant neoplasm of skin of unspecified ear and external auricular canal |
| C44.292 | Other specified malignant neoplasm of skin of right ear and external auricular canal |
| C44.299 | Other specified malignant neoplasm of skin of left ear and external auricular canal |
| C44.3 | Other and unspecified malignant neoplasm of skin of other and unspecified parts of face |
| C44.30 | Unspecified malignant neoplasm of skin of other and unspecified parts of face |
| C44.300 | Unspecified malignant neoplasm of skin of unspecified part of face |
| C44.301 | Unspecified malignant neoplasm of skin of nose |
| C44.309 | Unspecified malignant neoplasm of skin of other parts of face |
| C44.31 | Basal cell carcinoma of skin of other and unspecified parts of face |
| C44.310 | Basal cell carcinoma of skin of unspecified parts of face |
| C44.311 | Basal cell carcinoma of skin of nose |
| C44.319 | Basal cell carcinoma of skin of other parts of face |
| C44.32 | Squamous cell carcinoma of skin of other and unspecified parts of face |
| C44.320 | Squamous cell carcinoma of skin of unspecified parts of face |
| C44.321 | Squamous cell carcinoma of skin of nose |
| C44.329 | Squamous cell carcinoma of skin of other parts of face |
| C44.39 | Other specified malignant neoplasm of skin of other and unspecified parts of face |
| C44.390 | Other specified malignant neoplasm of skin of unspecified parts of face |
| C44.391 | Other specified malignant neoplasm of skin of nose |
| C44.399 | Other specified malignant neoplasm of skin of other parts of face |
| C44.4 | Other and unspecified malignant neoplasm of skin of scalp and neck |
| C44.40 | Unspecified malignant neoplasm of skin of scalp and neck |
| C44.41 | Basal cell carcinoma of skin of scalp and neck |
| C44.42 | Squamous cell carcinoma of skin of scalp and neck |
| C44.49 | Other specified malignant neoplasm of skin of scalp and neck |
| C44.5 | Other and unspecified malignant neoplasm of skin of trunk |
| C44.50 | Unspecified malignant neoplasm of skin of trunk |
| C44.500 | Unspecified malignant neoplasm of anal skin |
| C44.501 | Unspecified malignant neoplasm of skin of breast |
| C44.509 | Unspecified malignant neoplasm of skin of other part of trunk |
| C44.51 | Basal cell carcinoma of skin of trunk |
| C44.510 | Basal cell carcinoma of anal skin |
| C44.511 | Basal cell carcinoma of skin of breast |
| C44.519 | Basal cell carcinoma of skin of other part of trunk |
| C44.52 | Squamous cell carcinoma of skin of trunk |
| C44.520 | Squamous cell carcinoma of anal skin |
| C44.521 | Squamous cell carcinoma of skin of breast |
| C44.529 | Squamous cell carcinoma of skin of other part of trunk |
| C44.59 | Other specified malignant neoplasm of skin of trunk |
| C44.590 | Other specified malignant neoplasm of anal skin |
| C44.591 | Other specified malignant neoplasm of skin of breast |
| C44.599 | Other specified malignant neoplasm of skin of other part of trunk |
| C44.6 | Other and unspecified malignant neoplasm of skin of upper limb, including shoulder |
| C44.60 | Unspecified malignant neoplasm of skin of upper limb, including shoulder |
| C44.601 | Unspecified malignant neoplasm of skin of unspecified upper limb, including shoulder |
| C44.602 | Unspecified malignant neoplasm of skin of right upper limb, including shoulder |
| C44.609 | Unspecified malignant neoplasm of skin of left upper limb, including shoulder |
| C44.61 | Basal cell carcinoma of skin of upper limb, including shoulder |
| C44.611 | Basal cell carcinoma of skin of unspecified upper limb, including shoulder |
| C44.612 | Basal cell carcinoma of skin of right upper limb, including shoulder |
| C44.619 | Basal cell carcinoma of skin of left upper limb, including shoulder |
| C44.62 | Squamous cell carcinoma of skin of upper limb, including shoulder |
| C44.621 | Squamous cell carcinoma of skin of unspecified upper limb, including shoulder |
| C44.622 | Squamous cell carcinoma of skin of right upper limb, including shoulder |
| C44.629 | Squamous cell carcinoma of skin of left upper limb, including shoulder |
| C44.69 | Other specified malignant neoplasm of skin of upper limb, including shoulder |
| C44.691 | Other specified malignant neoplasm of skin of unspecified upper limb, including shoulder |
| C44.692 | Other specified malignant neoplasm of skin of right upper limb, including shoulder |
| C44.699 | Other specified malignant neoplasm of skin of left upper limb, including shoulder |
| C44.7 | Other and unspecified malignant neoplasm of skin of lower limb, including hip |
| C44.70 | Unspecified malignant neoplasm of skin of lower limb, including hip |
| C44.701 | Unspecified malignant neoplasm of skin of unspecified lower limb, including hip |
| C44.702 | Unspecified malignant neoplasm of skin of right lower limb, including hip |
| C44.709 | Unspecified malignant neoplasm of skin of left lower limb, including hip |
| C44.71 | Basal cell carcinoma of skin of lower limb, including hip |
| C44.711 | Basal cell carcinoma of skin of unspecified lower limb, including hip |
| C44.712 | Basal cell carcinoma of skin of right lower limb, including hip |
| C44.719 | Basal cell carcinoma of skin of left lower limb, including hip |
| C44.72 | Squamous cell carcinoma of skin of lower limb, including hip |
| C44.721 | Squamous cell carcinoma of skin of unspecified lower limb, including hip |
| C44.722 | Squamous cell carcinoma of skin of right lower limb, including hip |
| C44.729 | Squamous cell carcinoma of skin of left lower limb, including hip |
| C44.79 | Other specified malignant neoplasm of skin of lower limb, including hip |
| C44.791 | Other specified malignant neoplasm of skin of unspecified lower limb, including hip |
| C44.792 | Other specified malignant neoplasm of skin of right lower limb, including hip |
| C44.799 | Other specified malignant neoplasm of skin of left lower limb, including hip |
| C44.8 | Other and unspecified malignant neoplasm of overlapping sites of skin |
| C44.80 | Unspecified malignant neoplasm of overlapping sites of skin |
| C44.81 | Basal cell carcinoma of overlapping sites of skin |
| C44.82 | Squamous cell carcinoma of overlapping sites of skin |
| C44.89 | Other specified malignant neoplasm of overlapping sites of skin |
| C44.9 | Other and unspecified malignant neoplasm of skin, unspecified |
| C44.90 | Unspecified malignant neoplasm of skin, unspecified |
| C44.91 | Basal cell carcinoma of skin, unspecified |
| C44.92 | Squamous cell carcinoma of skin, unspecified |
| C44.99 | Other specified malignant neoplasm of skin, unspecified |
| C45 | Mesothelioma |
| C45.0 | Mesothelioma of pleura |
| C45.1 | Mesothelioma of peritoneum |
| C45.2 | Mesothelioma of pericardium |
| C45.7 | Mesothelioma of other sites |
| C45.9 | Mesothelioma, unspecified |
| C46 | Kaposi's sarcoma |
| C46.0 | Kaposi's sarcoma of skin |
| C46.1 | Kaposi's sarcoma of soft tissue |
| C46.2 | Kaposi's sarcoma of palate |
| C46.3 | Kaposi's sarcoma of lymph nodes |
| C46.4 | Kaposi's sarcoma of gastrointestinal sites |
| C46.5 | Kaposi's sarcoma of lung |
| C46.50 | Kaposi's sarcoma of unspecified lung |
| C46.51 | Kaposi's sarcoma of right lung |
| C46.52 | Kaposi's sarcoma of left lung |
| C46.7 | Kaposi's sarcoma of other sites |
| C46.9 | Kaposi's sarcoma, unspecified |
| C47 | Malignant neoplasm of peripheral nerves and autonomic nervous system |
| C47.0 | Malignant neoplasm of peripheral nerves of head, face and neck |
| C47.1 | Malignant neoplasm of peripheral nerves of upper limb, including shoulder |
| C47.10 | Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder |
| C47.11 | Malignant neoplasm of peripheral nerves of right upper limb, including shoulder |
| C47.12 | Malignant neoplasm of peripheral nerves of left upper limb, including shoulder |
| C47.2 | Malignant neoplasm of peripheral nerves of lower limb, including hip |
| C47.20 | Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip |
| C47.21 | Malignant neoplasm of peripheral nerves of right lower limb, including hip |
| C47.22 | Malignant neoplasm of peripheral nerves of left lower limb, including hip |
| C47.3 | Malignant neoplasm of peripheral nerves of thorax |
| C47.4 | Malignant neoplasm of peripheral nerves of abdomen |
| C47.5 | Malignant neoplasm of peripheral nerves of pelvis |
| C47.6 | Malignant neoplasm of peripheral nerves of trunk, unspecified |
| C47.8 | Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system |
| C47.9 | Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified |
| C48 | Malignant neoplasm of retroperitoneum and peritoneum |
| C48.0 | Malignant neoplasm of retroperitoneum |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C49 | Malignant neoplasm of other connective and soft tissue |
| C49.0 | Malignant neoplasm of connective and soft tissue of head, face and neck |
| C49.1 | Malignant neoplasm of connective and soft tissue of upper limb, including shoulder |
| C49.10 | Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder |
| C49.11 | Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder |
| C49.12 | Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder |
| C49.2 | Malignant neoplasm of connective and soft tissue of lower limb, including hip |
| C49.20 | Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip |
| C49.21 | Malignant neoplasm of connective and soft tissue of right lower limb, including hip |
| C49.22 | Malignant neoplasm of connective and soft tissue of left lower limb, including hip |
| C49.3 | Malignant neoplasm of connective and soft tissue of thorax |
| C49.4 | Malignant neoplasm of connective and soft tissue of abdomen |
| C49.5 | Malignant neoplasm of connective and soft tissue of pelvis |
| C49.6 | Malignant neoplasm of connective and soft tissue of trunk, unspecified |
| C49.8 | Malignant neoplasm of overlapping sites of connective and soft tissue |
| C49.9 | Malignant neoplasm of connective and soft tissue, unspecified |
| C4A | Merkel cell carcinoma |
| C4A.0 | Merkel cell carcinoma of lip |
| C4A.1 | Merkel cell carcinoma of eyelid, including canthus |
| C4A.10 | Merkel cell carcinoma of unspecified eyelid, including canthus |
| C4A.11 | Merkel cell carcinoma of right eyelid, including canthus |
| C4A.111 | Merkel cell carcinoma of right upper eyelid, including canthus |
| C4A.112 | Merkel cell carcinoma of right lower eyelid, including canthus |
| C4A.12 | Merkel cell carcinoma of left eyelid, including canthus |
| C4A.121 | Merkel cell carcinoma of left upper eyelid, including canthus |
| C4A.122 | Merkel cell carcinoma of left lower eyelid, including canthus |
| C4A.2 | Merkel cell carcinoma of ear and external auricular canal |
| C4A.20 | Merkel cell carcinoma of unspecified ear and external auricular canal |
| C4A.21 | Merkel cell carcinoma of right ear and external auricular canal |
| C4A.22 | Merkel cell carcinoma of left ear and external auricular canal |
| C4A.3 | Merkel cell carcinoma of other and unspecified parts of face |
| C4A.30 | Merkel cell carcinoma of unspecified part of face |
| C4A.31 | Merkel cell carcinoma of nose |
| C4A.39 | Merkel cell carcinoma of other parts of face |
| C4A.4 | Merkel cell carcinoma of scalp and neck |
| C4A.5 | Merkel cell carcinoma of trunk |
| C4A.51 | Merkel cell carcinoma of anal skin |
| C4A.52 | Merkel cell carcinoma of skin of breast |
| C4A.59 | Merkel cell carcinoma of other part of trunk |
| C4A.6 | Merkel cell carcinoma of upper limb, including shoulder |
| C4A.60 | Merkel cell carcinoma of unspecified upper limb, including shoulder |
| C4A.61 | Merkel cell carcinoma of right upper limb, including shoulder |
| C4A.62 | Merkel cell carcinoma of left upper limb, including shoulder |
| C4A.7 | Merkel cell carcinoma of lower limb, including hip |
| C4A.70 | Merkel cell carcinoma of unspecified lower limb, including hip |
| C4A.71 | Merkel cell carcinoma of right lower limb, including hip |
| C4A.72 | Merkel cell carcinoma of left lower limb, including hip |
| C4A.8 | Merkel cell carcinoma of overlapping sites |
| C4A.9 | Merkel cell carcinoma, unspecified |
| C50 | Malignant neoplasm of breast |
| C50.0 | Malignant neoplasm of nipple and areola |
| C50.01 | Malignant neoplasm of nipple and areola, female |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast |
| C50.019 | Malignant neoplasm of nipple and areola, unspecified female breast |
| C50.02 | Malignant neoplasm of nipple and areola, male |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast |
| C50.029 | Malignant neoplasm of nipple and areola, unspecified male breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.12 | Malignant neoplasm of central portion of breast, male |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.22 | Malignant neoplasm of upper-inner quadrant of breast, male |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.32 | Malignant neoplasm of lower-inner quadrant of breast, male |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.42 | Malignant neoplasm of upper-outer quadrant of breast, male |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.52 | Malignant neoplasm of lower-outer quadrant of breast, male |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.62 | Malignant neoplasm of axillary tail of breast, male |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.82 | Malignant neoplasm of overlapping sites of breast, male |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.92 | Malignant neoplasm of breast of unspecified site, male |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
| C51 | Malignant neoplasm of vulva |
| C51.0 | Malignant neoplasm of labium majus |
| C51.1 | Malignant neoplasm of labium minus |
| C51.2 | Malignant neoplasm of clitoris |
| C51.8 | Malignant neoplasm of overlapping sites of vulva |
| C51.9 | Malignant neoplasm of vulva, unspecified |
| C52 | Malignant neoplasm of vagina |
| C53 | Malignant neoplasm of cervix uteri |
| C53.0 | Malignant neoplasm of endocervix |
| C53.1 | Malignant neoplasm of exocervix |
| C53.8 | Malignant neoplasm of overlapping sites of cervix uteri |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified |
| C54 | Malignant neoplasm of corpus uteri |
| C54.0 | Malignant neoplasm of isthmus uteri |
| C54.1 | Malignant neoplasm of endometrium |
| C54.2 | Malignant neoplasm of myometrium |
| C54.3 | Malignant neoplasm of fundus uteri |
| C54.8 | Malignant neoplasm of overlapping sites of corpus uteri |
| C54.9 | Malignant neoplasm of corpus uteri, unspecified |
| C55 | Malignant neoplasm of uterus, part unspecified |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.3 | Malignant neoplasm of bilateral ovaries |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57 | Malignant neoplasm of other and unspecified female genital organs |
| C57.0 | Malignant neoplasm of fallopian tube |
| C57.00 | Malignant neoplasm of unspecified fallopian tube |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| C57.1 | Malignant neoplasm of broad ligament |
| C57.10 | Malignant neoplasm of unspecified broad ligament |
| C57.11 | Malignant neoplasm of right broad ligament |
| C57.12 | Malignant neoplasm of left broad ligament |
| C57.2 | Malignant neoplasm of round ligament |
| C57.20 | Malignant neoplasm of unspecified round ligament |
| C57.21 | Malignant neoplasm of right round ligament |
| C57.22 | Malignant neoplasm of left round ligament |
| C57.3 | Malignant neoplasm of parametrium |
| C57.4 | Malignant neoplasm of uterine adnexa, unspecified |
| C57.7 | Malignant neoplasm of other specified female genital organs |
| C57.8 | Malignant neoplasm of overlapping sites of female genital organs |
| C57.9 | Malignant neoplasm of female genital organ, unspecified |
| C58 | Malignant neoplasm of placenta |
| C60 | Malignant neoplasm of penis |
| C60.0 | Malignant neoplasm of prepuce |
| C60.1 | Malignant neoplasm of glans penis |
| C60.2 | Malignant neoplasm of body of penis |
| C60.8 | Malignant neoplasm of overlapping sites of penis |
| C60.9 | Malignant neoplasm of penis, unspecified |
| C61 | Malignant neoplasm of prostate |
| C62 | Malignant neoplasm of testis |
| C62.0 | Malignant neoplasm of undescended testis |
| C62.00 | Malignant neoplasm of unspecified undescended testis |
| C62.01 | Malignant neoplasm of undescended right testis |
| C62.02 | Malignant neoplasm of undescended left testis |
| C62.1 | Malignant neoplasm of descended testis |
| C62.10 | Malignant neoplasm of unspecified descended testis |
| C62.11 | Malignant neoplasm of descended right testis |
| C62.12 | Malignant neoplasm of descended left testis |
| C62.9 | Malignant neoplasm of testis, unspecified whether descended or undescended |
| C62.90 | Malignant neoplasm of unspecified testis, unspecified whether descended or undescended |
| C62.91 | Malignant neoplasm of right testis, unspecified whether descended or undescended |
| C62.92 | Malignant neoplasm of left testis, unspecified whether descended or undescended |
| C63 | Malignant neoplasm of other and unspecified male genital organs |
| C63.0 | Malignant neoplasm of epididymis |
| C63.00 | Malignant neoplasm of unspecified epididymis |
| C63.01 | Malignant neoplasm of right epididymis |
| C63.02 | Malignant neoplasm of left epididymis |
| C63.1 | Malignant neoplasm of spermatic cord |
| C63.10 | Malignant neoplasm of unspecified spermatic cord |
| C63.11 | Malignant neoplasm of right spermatic cord |
| C63.12 | Malignant neoplasm of left spermatic cord |
| C63.2 | Malignant neoplasm of scrotum |
| C63.7 | Malignant neoplasm of other specified male genital organs |
| C63.8 | Malignant neoplasm of overlapping sites of male genital organs |
| C63.9 | Malignant neoplasm of male genital organ, unspecified |
| C64 | Malignant neoplasm of kidney, except renal pelvis |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
| C65 | Malignant neoplasm of renal pelvis |
| C65.1 | Malignant neoplasm of right renal pelvis |
| C65.2 | Malignant neoplasm of left renal pelvis |
| C65.9 | Malignant neoplasm of unspecified renal pelvis |
| C66 | Malignant neoplasm of ureter |
| C66.1 | Malignant neoplasm of right ureter |
| C66.2 | Malignant neoplasm of left ureter |
| C66.9 | Malignant neoplasm of unspecified ureter |
| C67 | Malignant neoplasm of bladder |
| C67.0 | Malignant neoplasm of trigone of bladder |
| C67.1 | Malignant neoplasm of dome of bladder |
| C67.2 | Malignant neoplasm of lateral wall of bladder |
| C67.3 | Malignant neoplasm of anterior wall of bladder |
| C67.4 | Malignant neoplasm of posterior wall of bladder |
| C67.5 | Malignant neoplasm of bladder neck |
| C67.6 | Malignant neoplasm of ureteric orifice |
| C67.7 | Malignant neoplasm of urachus |
| C67.8 | Malignant neoplasm of overlapping sites of bladder |
| C67.9 | Malignant neoplasm of bladder, unspecified |
| C68 | Malignant neoplasm of other and unspecified urinary organs |
| C68.0 | Malignant neoplasm of urethra |
| C68.1 | Malignant neoplasm of paraurethral glands |
| C68.8 | Malignant neoplasm of overlapping sites of urinary organs |
| C68.9 | Malignant neoplasm of urinary organ, unspecified |
| C69 | Malignant neoplasm of eye and adnexa |
| C69.0 | Malignant neoplasm of conjunctiva |
| C69.00 | Malignant neoplasm of unspecified conjunctiva |
| C69.01 | Malignant neoplasm of right conjunctiva |
| C69.02 | Malignant neoplasm of left conjunctiva |
| C69.1 | Malignant neoplasm of cornea |
| C69.10 | Malignant neoplasm of unspecified cornea |
| C69.11 | Malignant neoplasm of right cornea |
| C69.12 | Malignant neoplasm of left cornea |
| C69.2 | Malignant neoplasm of retina |
| C69.20 | Malignant neoplasm of unspecified retina |
| C69.21 | Malignant neoplasm of right retina |
| C69.22 | Malignant neoplasm of left retina |
| C69.3 | Malignant neoplasm of choroid |
| C69.30 | Malignant neoplasm of unspecified choroid |
| C69.31 | Malignant neoplasm of right choroid |
| C69.32 | Malignant neoplasm of left choroid |
| C69.4 | Malignant neoplasm of ciliary body |
| C69.40 | Malignant neoplasm of unspecified ciliary body |
| C69.41 | Malignant neoplasm of right ciliary body |
| C69.42 | Malignant neoplasm of left ciliary body |
| C69.5 | Malignant neoplasm of lacrimal gland and duct |
| C69.50 | Malignant neoplasm of unspecified lacrimal gland and duct |
| C69.51 | Malignant neoplasm of right lacrimal gland and duct |
| C69.52 | Malignant neoplasm of left lacrimal gland and duct |
| C69.6 | Malignant neoplasm of orbit |
| C69.60 | Malignant neoplasm of unspecified orbit |
| C69.61 | Malignant neoplasm of right orbit |
| C69.62 | Malignant neoplasm of left orbit |
| C69.8 | Malignant neoplasm of overlapping sites of eye and adnexa |
| C69.80 | Malignant neoplasm of overlapping sites of unspecified eye and adnexa |
| C69.81 | Malignant neoplasm of overlapping sites of right eye and adnexa |
| C69.82 | Malignant neoplasm of overlapping sites of left eye and adnexa |
| C69.9 | Malignant neoplasm of unspecified site of eye |
| C69.90 | Malignant neoplasm of unspecified site of unspecified eye |
| C69.91 | Malignant neoplasm of unspecified site of right eye |
| C69.92 | Malignant neoplasm of unspecified site of left eye |
| C70 | Malignant neoplasm of meninges |
| C70.0 | Malignant neoplasm of cerebral meninges |
| C70.1 | Malignant neoplasm of spinal meninges |
| C70.9 | Malignant neoplasm of meninges, unspecified |
| C71 | Malignant neoplasm of brain |
| C71.0 | Malignant neoplasm of cerebrum, except lobes and ventricles |
| C71.1 | Malignant neoplasm of frontal lobe |
| C71.2 | Malignant neoplasm of temporal lobe |
| C71.3 | Malignant neoplasm of parietal lobe |
| C71.4 | Malignant neoplasm of occipital lobe |
| C71.5 | Malignant neoplasm of cerebral ventricle |
| C71.6 | Malignant neoplasm of cerebellum |
| C71.7 | Malignant neoplasm of brain stem |
| C71.8 | Malignant neoplasm of overlapping sites of brain |
| C71.9 | Malignant neoplasm of brain, unspecified |
| C72 | Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system |
| C72.0 | Malignant neoplasm of spinal cord |
| C72.1 | Malignant neoplasm of cauda equina |
| C72.2 | Malignant neoplasm of olfactory nerve |
| C72.20 | Malignant neoplasm of unspecified olfactory nerve |
| C72.21 | Malignant neoplasm of right olfactory nerve |
| C72.22 | Malignant neoplasm of left olfactory nerve |
| C72.3 | Malignant neoplasm of optic nerve |
| C72.30 | Malignant neoplasm of unspecified optic nerve |
| C72.31 | Malignant neoplasm of right optic nerve |
| C72.32 | Malignant neoplasm of left optic nerve |
| C72.4 | Malignant neoplasm of acoustic nerve |
| C72.40 | Malignant neoplasm of unspecified acoustic nerve |
| C72.41 | Malignant neoplasm of right acoustic nerve |
| C72.42 | Malignant neoplasm of left acoustic nerve |
| C72.5 | Malignant neoplasm of other and unspecified cranial nerves |
| C72.50 | Malignant neoplasm of unspecified cranial nerve |
| C72.59 | Malignant neoplasm of other cranial nerves |
| C72.9 | Malignant neoplasm of central nervous system, unspecified |
| C73 | Malignant neoplasm of thyroid gland |
| C74 | Malignant neoplasm of adrenal gland |
| C74.0 | Malignant neoplasm of cortex of adrenal gland |
| C74.00 | Malignant neoplasm of cortex of unspecified adrenal gland |
| C74.01 | Malignant neoplasm of cortex of right adrenal gland |
| C74.02 | Malignant neoplasm of cortex of left adrenal gland |
| C74.1 | Malignant neoplasm of medulla of adrenal gland |
| C74.10 | Malignant neoplasm of medulla of unspecified adrenal gland |
| C74.11 | Malignant neoplasm of medulla of right adrenal gland |
| C74.12 | Malignant neoplasm of medulla of left adrenal gland |
| C74.9 | Malignant neoplasm of unspecified part of adrenal gland |
| C74.90 | Malignant neoplasm of unspecified part of unspecified adrenal gland |
| C74.91 | Malignant neoplasm of unspecified part of right adrenal gland |
| C74.92 | Malignant neoplasm of unspecified part of left adrenal gland |
| C75 | Malignant neoplasm of other endocrine glands and related structures |
| C75.0 | Malignant neoplasm of parathyroid gland |
| C75.1 | Malignant neoplasm of pituitary gland |
| C75.2 | Malignant neoplasm of craniopharyngeal duct |
| C75.3 | Malignant neoplasm of pineal gland |
| C75.4 | Malignant neoplasm of carotid body |
| C75.5 | Malignant neoplasm of aortic body and other paraganglia |
| C75.8 | Malignant neoplasm with pluriglandular involvement, unspecified |
| C75.9 | Malignant neoplasm of endocrine gland, unspecified |
| C76 | Malignant neoplasm of other and ill-defined sites |
| C76.0 | Malignant neoplasm of head, face and neck |
| C76.1 | Malignant neoplasm of thorax |
| C76.2 | Malignant neoplasm of abdomen |
| C76.3 | Malignant neoplasm of pelvis |
| C76.4 | Malignant neoplasm of upper limb |
| C76.40 | Malignant neoplasm of unspecified upper limb |
| C76.41 | Malignant neoplasm of right upper limb |
| C76.42 | Malignant neoplasm of left upper limb |
| C76.5 | Malignant neoplasm of lower limb |
| C76.50 | Malignant neoplasm of unspecified lower limb |
| C76.51 | Malignant neoplasm of right lower limb |
| C76.52 | Malignant neoplasm of left lower limb |
| C76.8 | Malignant neoplasm of other specified ill-defined sites |
| C79.63 | Secondary malignant neoplasm of bilateral ovaries |
| C7A | Malignant neuroendocrine tumors |
| C7A.00 | Malignant carcinoid tumor of unspecified site |
| C7A.01 | Malignant carcinoid tumors of the small intestine |
| C7A.010 | Malignant carcinoid tumor of the duodenum |
| C7A.011 | Malignant carcinoid tumor of the jejunum |
| C7A.012 | Malignant carcinoid tumor of the ileum |
| C7A.019 | Malignant carcinoid tumor of the small intestine, unspecified portion |
| C7A.02 | Malignant carcinoid tumors of the appendix, large intestine, and rectum |
| C7A.020 | Malignant carcinoid tumor of the appendix |
| C7A.021 | Malignant carcinoid tumor of the cecum |
| C7A.022 | Malignant carcinoid tumor of the ascending colon |
| C7A.023 | Malignant carcinoid tumor of the transverse colon |
| C7A.024 | Malignant carcinoid tumor of the descending colon |
| C7A.025 | Malignant carcinoid tumor of the sigmoid colon |
| C7A.026 | Malignant carcinoid tumor of the rectum |
| C7A.029 | Malignant carcinoid tumor of the large intestine, unspecified portion |
| C7A.09 | Malignant carcinoid tumors of other sites |
| C7A.090 | Malignant carcinoid tumor of the bronchus and lung |
| C7A.091 | Malignant carcinoid tumor of the thymus |
| C7A.092 | Malignant carcinoid tumor of the stomach |
| C7A.093 | Malignant carcinoid tumor of the kidney |
| C7A.094 | Malignant carcinoid tumor of the foregut, unspecified |
| C7A.095 | Malignant carcinoid tumor of the midgut, unspecified |
| C7A.096 | Malignant carcinoid tumor of the hindgut, unspecified |
| C7A.098 | Malignant carcinoid tumors of other sites |
| C7A.1 | Malignant poorly differentiated neuroendocrine tumors |
| C7A.8 | Other malignant neuroendocrine tumors |
| C80 | Malignant neoplasm without specification of site |
| C80.0 | Disseminated malignant neoplasm, unspecified |
| C80.1 | Malignant (primary) neoplasm, unspecified |
| C80.2 | Malignant neoplasm associated with transplanted organ |
| C81 | Hodgkin lymphoma |
| C81.0 | Nodular lymphocyte predominant hodgkin lymphoma |
| C81.00 | Nodular lymphocyte predominant hodgkin lymphoma, unspecified site |
| C81.01 | Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.02 | Nodular lymphocyte predominant hodgkin lymphoma, intrathoracic lymph nodes |
| C81.03 | Nodular lymphocyte predominant hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.04 | Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.05 | Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.06 | Nodular lymphocyte predominant hodgkin lymphoma, intrapelvic lymph nodes |
| C81.07 | Nodular lymphocyte predominant hodgkin lymphoma, spleen |
| C81.08 | Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of multiple sites |
| C81.09 | Nodular lymphocyte predominant hodgkin lymphoma, extranodal and solid organ sites |
| C81.1 | Nodular sclerosis hodgkin lymphoma |
| C81.10 | Nodular sclerosis hodgkin lymphoma, unspecified site |
| C81.11 | Nodular sclerosis hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.12 | Nodular sclerosis hodgkin lymphoma, intrathoracic lymph nodes |
| C81.13 | Nodular sclerosis hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.14 | Nodular sclerosis hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.15 | Nodular sclerosis hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.16 | Nodular sclerosis hodgkin lymphoma, intrapelvic lymph nodes |
| C81.17 | Nodular sclerosis hodgkin lymphoma, spleen |
| C81.18 | Nodular sclerosis hodgkin lymphoma, lymph nodes of multiple sites |
| C81.19 | Nodular sclerosis hodgkin lymphoma, extranodal and solid organ sites |
| C81.2 | Mixed cellularity hodgkin lymphoma |
| C81.20 | Mixed cellularity hodgkin lymphoma, unspecified site |
| C81.21 | Mixed cellularity hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.22 | Mixed cellularity hodgkin lymphoma, intrathoracic lymph nodes |
| C81.23 | Mixed cellularity hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.24 | Mixed cellularity hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.25 | Mixed cellularity hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.26 | Mixed cellularity hodgkin lymphoma, intrapelvic lymph nodes |
| C81.27 | Mixed cellularity hodgkin lymphoma, spleen |
| C81.28 | Mixed cellularity hodgkin lymphoma, lymph nodes of multiple sites |
| C81.29 | Mixed cellularity hodgkin lymphoma, extranodal and solid organ sites |
| C81.3 | Lymphocyte depleted hodgkin lymphoma |
| C81.30 | Lymphocyte depleted hodgkin lymphoma, unspecified site |
| C81.31 | Lymphocyte depleted hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.32 | Lymphocyte depleted hodgkin lymphoma, intrathoracic lymph nodes |
| C81.33 | Lymphocyte depleted hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.34 | Lymphocyte depleted hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.35 | Lymphocyte depleted hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.36 | Lymphocyte depleted hodgkin lymphoma, intrapelvic lymph nodes |
| C81.37 | Lymphocyte depleted hodgkin lymphoma, spleen |
| C81.38 | Lymphocyte depleted hodgkin lymphoma, lymph nodes of multiple sites |
| C81.39 | Lymphocyte depleted hodgkin lymphoma, extranodal and solid organ sites |
| C81.4 | Lymphocyte-rich hodgkin lymphoma |
| C81.40 | Lymphocyte-rich hodgkin lymphoma, unspecified site |
| C81.41 | Lymphocyte-rich hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.42 | Lymphocyte-rich hodgkin lymphoma, intrathoracic lymph nodes |
| C81.43 | Lymphocyte-rich hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.44 | Lymphocyte-rich hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.45 | Lymphocyte-rich hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.46 | Lymphocyte-rich hodgkin lymphoma, intrapelvic lymph nodes |
| C81.47 | Lymphocyte-rich hodgkin lymphoma, spleen |
| C81.48 | Lymphocyte-rich hodgkin lymphoma, lymph nodes of multiple sites |
| C81.49 | Lymphocyte-rich hodgkin lymphoma, extranodal and solid organ sites |
| C81.7 | Other hodgkin lymphoma |
| C81.70 | Other hodgkin lymphoma, unspecified site |
| C81.71 | Other hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.72 | Other hodgkin lymphoma, intrathoracic lymph nodes |
| C81.73 | Other hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.74 | Other hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.75 | Other hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.76 | Other hodgkin lymphoma, intrapelvic lymph nodes |
| C81.77 | Other hodgkin lymphoma, spleen |
| C81.78 | Other hodgkin lymphoma, lymph nodes of multiple sites |
| C81.79 | Other hodgkin lymphoma, extranodal and solid organ sites |
| C81.9 | Hodgkin lymphoma, unspecified |
| C81.90 | Hodgkin lymphoma, unspecified, unspecified site |
| C81.91 | Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck |
| C81.92 | Hodgkin lymphoma, unspecified, intrathoracic lymph nodes |
| C81.93 | Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes |
| C81.94 | Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C81.95 | Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C81.96 | Hodgkin lymphoma, unspecified, intrapelvic lymph nodes |
| C81.97 | Hodgkin lymphoma, unspecified, spleen |
| C81.98 | Hodgkin lymphoma, unspecified, lymph nodes of multiple sites |
| C81.99 | Hodgkin lymphoma, unspecified, extranodal and solid organ sites |
| C82 | Follicular lymphoma |
| C82.0 | Follicular lymphoma grade I |
| C82.00 | Follicular lymphoma grade i, unspecified site |
| C82.01 | Follicular lymphoma grade i, lymph nodes of head, face, and neck |
| C82.02 | Follicular lymphoma grade i, intrathoracic lymph nodes |
| C82.03 | Follicular lymphoma grade i, intra-abdominal lymph nodes |
| C82.04 | Follicular lymphoma grade i, lymph nodes of axilla and upper limb |
| C82.05 | Follicular lymphoma grade i, lymph nodes of inguinal region and lower limb |
| C82.06 | Follicular lymphoma grade i, intrapelvic lymph nodes |
| C82.07 | Follicular lymphoma grade i, spleen |
| C82.08 | Follicular lymphoma grade i, lymph nodes of multiple sites |
| C82.09 | Follicular lymphoma grade i, extranodal and solid organ sites |
| C82.1 | Follicular lymphoma grade II |
| C82.10 | Follicular lymphoma grade Ii, unspecified site |
| C82.11 | Follicular lymphoma grade Ii, lymph nodes of head, face, and neck |
| C82.12 | Follicular lymphoma grade Ii, intrathoracic lymph nodes |
| C82.13 | Follicular lymphoma grade Ii, intra-abdominal lymph nodes |
| C82.14 | Follicular lymphoma grade Ii, lymph nodes of axilla and upper limb |
| C82.15 | Follicular lymphoma grade Ii, lymph nodes of inguinal region and lower limb |
| C82.16 | Follicular lymphoma grade Ii, intrapelvic lymph nodes |
| C82.17 | Follicular lymphoma grade Ii, spleen |
| C82.18 | Follicular lymphoma grade Ii, lymph nodes of multiple sites |
| C82.19 | Follicular lymphoma grade Ii, extranodal and solid organ sites |
| C82.2 | Follicular lymphoma grade IIi, unspecified |
| C82.20 | Follicular lymphoma grade IIi, unspecified, unspecified site |
| C82.21 | Follicular lymphoma grade IIi, unspecified, lymph nodes of head, face, and neck |
| C82.22 | Follicular lymphoma grade IIi, unspecified, intrathoracic lymph nodes |
| C82.23 | Follicular lymphoma grade IIi, unspecified, intra-abdominal lymph nodes |
| C82.24 | Follicular lymphoma grade IIi, unspecified, lymph nodes of axilla and upper limb |
| C82.25 | Follicular lymphoma grade IIi, unspecified, lymph nodes of inguinal region and lower limb |
| C82.26 | Follicular lymphoma grade IIi, unspecified, intrapelvic lymph nodes |
| C82.27 | Follicular lymphoma grade IIi, unspecified, spleen |
| C82.28 | Follicular lymphoma grade IIi, unspecified, lymph nodes of multiple sites |
| C82.29 | Follicular lymphoma grade IIi, unspecified, extranodal and solid organ sites |
| C82.3 | Follicular lymphoma grade IIia |
| C82.30 | Follicular lymphoma grade IIia, unspecified site |
| C82.31 | Follicular lymphoma grade IIia, lymph nodes of head, face, and neck |
| C82.32 | Follicular lymphoma grade IIia, intrathoracic lymph nodes |
| C82.33 | Follicular lymphoma grade IIia, intra-abdominal lymph nodes |
| C82.34 | Follicular lymphoma grade IIia, lymph nodes of axilla and upper limb |
| C82.35 | Follicular lymphoma grade IIia, lymph nodes of inguinal region and lower limb |
| C82.36 | Follicular lymphoma grade IIia, intrapelvic lymph nodes |
| C82.37 | Follicular lymphoma grade IIia, spleen |
| C82.38 | Follicular lymphoma grade IIia, lymph nodes of multiple sites |
| C82.39 | Follicular lymphoma grade IIia, extranodal and solid organ sites |
| C82.4 | Follicular lymphoma grade IIib |
| C82.40 | Follicular lymphoma grade IIib, unspecified site |
| C82.41 | Follicular lymphoma grade IIib, lymph nodes of head, face, and neck |
| C82.42 | Follicular lymphoma grade IIib, intrathoracic lymph nodes |
| C82.43 | Follicular lymphoma grade IIib, intra-abdominal lymph nodes |
| C82.44 | Follicular lymphoma grade IIib, lymph nodes of axilla and upper limb |
| C82.45 | Follicular lymphoma grade IIib, lymph nodes of inguinal region and lower limb |
| C82.46 | Follicular lymphoma grade IIib, intrapelvic lymph nodes |
| C82.47 | Follicular lymphoma grade IIib, spleen |
| C82.48 | Follicular lymphoma grade IIib, lymph nodes of multiple sites |
| C82.49 | Follicular lymphoma grade IIib, extranodal and solid organ sites |
| C82.5 | Diffuse follicle center lymphoma |
| C82.50 | Diffuse follicle center lymphoma, unspecified site |
| C82.51 | Diffuse follicle center lymphoma, lymph nodes of head, face, and neck |
| C82.52 | Diffuse follicle center lymphoma, intrathoracic lymph nodes |
| C82.53 | Diffuse follicle center lymphoma, intra-abdominal lymph nodes |
| C82.54 | Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb |
| C82.55 | Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb |
| C82.56 | Diffuse follicle center lymphoma, intrapelvic lymph nodes |
| C82.57 | Diffuse follicle center lymphoma, spleen |
| C82.58 | Diffuse follicle center lymphoma, lymph nodes of multiple sites |
| C82.59 | Diffuse follicle center lymphoma, extranodal and solid organ sites |
| C82.6 | Cutaneous follicle center lymphoma |
| C82.60 | Cutaneous follicle center lymphoma, unspecified site |
| C82.61 | Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck |
| C82.62 | Cutaneous follicle center lymphoma, intrathoracic lymph nodes |
| C82.63 | Cutaneous follicle center lymphoma, intra-abdominal lymph nodes |
| C82.64 | Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb |
| C82.65 | Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb |
| C82.66 | Cutaneous follicle center lymphoma, intrapelvic lymph nodes |
| C82.67 | Cutaneous follicle center lymphoma, spleen |
| C82.68 | Cutaneous follicle center lymphoma, lymph nodes of multiple sites |
| C82.69 | Cutaneous follicle center lymphoma, extranodal and solid organ sites |
| C82.8 | Other types of follicular lymphoma |
| C82.80 | Other types of follicular lymphoma, unspecified site |
| C82.81 | Other types of follicular lymphoma, lymph nodes of head, face, and neck |
| C82.82 | Other types of follicular lymphoma, intrathoracic lymph nodes |
| C82.83 | Other types of follicular lymphoma, intra-abdominal lymph nodes |
| C82.84 | Other types of follicular lymphoma, lymph nodes of axilla and upper limb |
| C82.85 | Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb |
| C82.86 | Other types of follicular lymphoma, intrapelvic lymph nodes |
| C82.87 | Other types of follicular lymphoma, spleen |
| C82.88 | Other types of follicular lymphoma, lymph nodes of multiple sites |
| C82.89 | Other types of follicular lymphoma, extranodal and solid organ sites |
| C82.9 | Follicular lymphoma, unspecified |
| C82.90 | Follicular lymphoma, unspecified, unspecified site |
| C82.91 | Follicular lymphoma, unspecified, lymph nodes of head, face, and neck |
| C82.92 | Follicular lymphoma, unspecified, intrathoracic lymph nodes |
| C82.93 | Follicular lymphoma, unspecified, intra-abdominal lymph nodes |
| C82.94 | Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C82.95 | Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C82.96 | Follicular lymphoma, unspecified, intrapelvic lymph nodes |
| C82.97 | Follicular lymphoma, unspecified, spleen |
| C82.98 | Follicular lymphoma, unspecified, lymph nodes of multiple sites |
| C82.99 | Follicular lymphoma, unspecified, extranodal and solid organ sites |
| C83 | Non-follicular lymphoma |
| C83.0 | Small cell b-cell lymphoma |
| C83.00 | Small cell b-cell lymphoma, unspecified site |
| C83.01 | Small cell b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.02 | Small cell b-cell lymphoma, intrathoracic lymph nodes |
| C83.03 | Small cell b-cell lymphoma, intra-abdominal lymph nodes |
| C83.04 | Small cell b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.05 | Small cell b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.06 | Small cell b-cell lymphoma, intrapelvic lymph nodes |
| C83.07 | Small cell b-cell lymphoma, spleen |
| C83.08 | Small cell b-cell lymphoma, lymph nodes of multiple sites |
| C83.09 | Small cell b-cell lymphoma, extranodal and solid organ sites |
| C83.1 | Mantle cell lymphoma |
| C83.10 | Mantle cell lymphoma, unspecified site |
| C83.11 | Mantle cell lymphoma, lymph nodes of head, face, and neck |
| C83.12 | Mantle cell lymphoma, intrathoracic lymph nodes |
| C83.13 | Mantle cell lymphoma, intra-abdominal lymph nodes |
| C83.14 | Mantle cell lymphoma, lymph nodes of axilla and upper limb |
| C83.15 | Mantle cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.16 | Mantle cell lymphoma, intrapelvic lymph nodes |
| C83.17 | Mantle cell lymphoma, spleen |
| C83.18 | Mantle cell lymphoma, lymph nodes of multiple sites |
| C83.19 | Mantle cell lymphoma, extranodal and solid organ sites |
| C83.3 | Diffuse large b-cell lymphoma |
| C83.30 | Diffuse large b-cell lymphoma, unspecified site |
| C83.31 | Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.32 | Diffuse large b-cell lymphoma, intrathoracic lymph nodes |
| C83.33 | Diffuse large b-cell lymphoma, intra-abdominal lymph nodes |
| C83.34 | Diffuse large b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.35 | Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.36 | Diffuse large b-cell lymphoma, intrapelvic lymph nodes |
| C83.37 | Diffuse large b-cell lymphoma, spleen |
| C83.38 | Diffuse large b-cell lymphoma, lymph nodes of multiple sites |
| C83.39 | Diffuse large b-cell lymphoma, extranodal and solid organ sites |
| C83.5 | Lymphoblastic (diffuse) lymphoma |
| C83.50 | Lymphoblastic (diffuse) lymphoma, unspecified site |
| C83.51 | Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck |
| C83.52 | Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes |
| C83.53 | Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes |
| C83.54 | Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb |
| C83.55 | Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb |
| C83.56 | Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes |
| C83.57 | Lymphoblastic (diffuse) lymphoma, spleen |
| C83.58 | Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites |
| C83.59 | Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites |
| C83.7 | Burkitt lymphoma |
| C83.70 | Burkitt lymphoma, unspecified site |
| C83.71 | Burkitt lymphoma, lymph nodes of head, face, and neck |
| C83.72 | Burkitt lymphoma, intrathoracic lymph nodes |
| C83.73 | Burkitt lymphoma, intra-abdominal lymph nodes |
| C83.74 | Burkitt lymphoma, lymph nodes of axilla and upper limb |
| C83.75 | Burkitt lymphoma, lymph nodes of inguinal region and lower limb |
| C83.76 | Burkitt lymphoma, intrapelvic lymph nodes |
| C83.77 | Burkitt lymphoma, spleen |
| C83.78 | Burkitt lymphoma, lymph nodes of multiple sites |
| C83.79 | Burkitt lymphoma, extranodal and solid organ sites |
| C83.8 | Other non-follicular lymphoma |
| C83.80 | Other non-follicular lymphoma, unspecified site |
| C83.81 | Other non-follicular lymphoma, lymph nodes of head, face, and neck |
| C83.82 | Other non-follicular lymphoma, intrathoracic lymph nodes |
| C83.83 | Other non-follicular lymphoma, intra-abdominal lymph nodes |
| C83.84 | Other non-follicular lymphoma, lymph nodes of axilla and upper limb |
| C83.85 | Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb |
| C83.86 | Other non-follicular lymphoma, intrapelvic lymph nodes |
| C83.87 | Other non-follicular lymphoma, spleen |
| C83.88 | Other non-follicular lymphoma, lymph nodes of multiple sites |
| C83.89 | Other non-follicular lymphoma, extranodal and solid organ sites |
| C83.9 | Non-follicular (diffuse) lymphoma, unspecified |
| C83.90 | Non-follicular (diffuse) lymphoma, unspecified, unspecified site |
| C83.91 | Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck |
| C83.92 | Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes |
| C83.93 | Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes |
| C83.94 | Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C83.95 | Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C83.96 | Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes |
| C83.97 | Non-follicular (diffuse) lymphoma, unspecified, spleen |
| C83.98 | Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites |
| C83.99 | Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites |
| C84 | Mature t/Nk-cell lymphomas |
| C84.0 | Mycosis fungoides |
| C84.00 | Mycosis fungoides, unspecified site |
| C84.01 | Mycosis fungoides, lymph nodes of head, face, and neck |
| C84.02 | Mycosis fungoides, intrathoracic lymph nodes |
| C84.03 | Mycosis fungoides, intra-abdominal lymph nodes |
| C84.04 | Mycosis fungoides, lymph nodes of axilla and upper limb |
| C84.05 | Mycosis fungoides, lymph nodes of inguinal region and lower limb |
| C84.06 | Mycosis fungoides, intrapelvic lymph nodes |
| C84.07 | Mycosis fungoides, spleen |
| C84.08 | Mycosis fungoides, lymph nodes of multiple sites |
| C84.09 | Mycosis fungoides, extranodal and solid organ sites |
| C84.1 | Sezary disease |
| C84.10 | Sezary disease, unspecified site |
| C84.11 | Sezary disease, lymph nodes of head, face, and neck |
| C84.12 | Sezary disease, intrathoracic lymph nodes |
| C84.13 | Sezary disease, intra-abdominal lymph nodes |
| C84.14 | Sezary disease, lymph nodes of axilla and upper limb |
| C84.15 | Sezary disease, lymph nodes of inguinal region and lower limb |
| C84.16 | Sezary disease, intrapelvic lymph nodes |
| C84.17 | Sezary disease, spleen |
| C84.18 | Sezary disease, lymph nodes of multiple sites |
| C84.19 | Sezary disease, extranodal and solid organ sites |
| C84.4 | Peripheral t-cell lymphoma, not elsewhere classified |
| C84.40 | Peripheral t-cell lymphoma, not elsewhere classified, unspecified site |
| C84.41 | Peripheral t-cell lymphoma, not elsewhere classified, lymph nodes of head, face, and neck |
| C84.42 | Peripheral t-cell lymphoma, not elsewhere classified, intrathoracic lymph nodes |
| C84.43 | Peripheral t-cell lymphoma, not elsewhere classified, intra-abdominal lymph nodes |
| C84.44 | Peripheral t-cell lymphoma, not elsewhere classified, lymph nodes of axilla and upper limb |
| C84.45 | Peripheral t-cell lymphoma, not elsewhere classified, lymph nodes of inguinal region and lower limb |
| C84.46 | Peripheral t-cell lymphoma, not elsewhere classified, intrapelvic lymph nodes |
| C84.47 | Peripheral t-cell lymphoma, not elsewhere classified, spleen |
| C84.48 | Peripheral t-cell lymphoma, not elsewhere classified, lymph nodes of multiple sites |
| C84.49 | Peripheral t-cell lymphoma, not elsewhere classified, extranodal and solid organ sites |
| C84.6 | Anaplastic large cell lymphoma, ALk-positive |
| C84.60 | Anaplastic large cell lymphoma, ALk-positive, unspecified site |
| C84.61 | Anaplastic large cell lymphoma, ALk-positive, lymph nodes of head, face, and neck |
| C84.62 | Anaplastic large cell lymphoma, ALk-positive, intrathoracic lymph nodes |
| C84.63 | Anaplastic large cell lymphoma, ALk-positive, intra-abdominal lymph nodes |
| C84.64 | Anaplastic large cell lymphoma, ALk-positive, lymph nodes of axilla and upper limb |
| C84.65 | Anaplastic large cell lymphoma, ALk-positive, lymph nodes of inguinal region and lower limb |
| C84.66 | Anaplastic large cell lymphoma, ALk-positive, intrapelvic lymph nodes |
| C84.67 | Anaplastic large cell lymphoma, ALk-positive, spleen |
| C84.68 | Anaplastic large cell lymphoma, ALk-positive, lymph nodes of multiple sites |
| C84.69 | Anaplastic large cell lymphoma, ALk-positive, extranodal and solid organ sites |
| C84.7 | Anaplastic large cell lymphoma, ALk-negative |
| C84.70 | Anaplastic large cell lymphoma, ALk-negative, unspecified site |
| C84.71 | Anaplastic large cell lymphoma, ALk-negative, lymph nodes of head, face, and neck |
| C84.72 | Anaplastic large cell lymphoma, ALk-negative, intrathoracic lymph nodes |
| C84.73 | Anaplastic large cell lymphoma, ALk-negative, intra-abdominal lymph nodes |
| C84.74 | Anaplastic large cell lymphoma, ALk-negative, lymph nodes of axilla and upper limb |
| C84.75 | Anaplastic large cell lymphoma, ALk-negative, lymph nodes of inguinal region and lower limb |
| C84.76 | Anaplastic large cell lymphoma, ALk-negative, intrapelvic lymph nodes |
| C84.77 | Anaplastic large cell lymphoma, ALk-negative, spleen |
| C84.78 | Anaplastic large cell lymphoma, ALk-negative, lymph nodes of multiple sites |
| C84.79 | Anaplastic large cell lymphoma, ALk-negative, extranodal and solid organ sites |
| C84.7A | Anaplastic large cell lymphoma, ALk-negative, breast |
| C84.9 | Mature t/Nk-cell lymphomas, unspecified |
| C84.90 | Mature t/Nk-cell lymphomas, unspecified, unspecified site |
| C84.91 | Mature t/Nk-cell lymphomas, unspecified, lymph nodes of head, face, and neck |
| C84.92 | Mature t/Nk-cell lymphomas, unspecified, intrathoracic lymph nodes |
| C84.93 | Mature t/Nk-cell lymphomas, unspecified, intra-abdominal lymph nodes |
| C84.94 | Mature t/Nk-cell lymphomas, unspecified, lymph nodes of axilla and upper limb |
| C84.95 | Mature t/Nk-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb |
| C84.96 | Mature t/Nk-cell lymphomas, unspecified, intrapelvic lymph nodes |
| C84.97 | Mature t/Nk-cell lymphomas, unspecified, spleen |
| C84.98 | Mature t/Nk-cell lymphomas, unspecified, lymph nodes of multiple sites |
| C84.99 | Mature t/Nk-cell lymphomas, unspecified, extranodal and solid organ sites |
| C84.A | Cutaneous t-cell lymphoma, unspecified |
| C84.A0 | Cutaneous t-cell lymphoma, unspecified, unspecified site |
| C84.A1 | Cutaneous t-cell lymphoma, unspecified lymph nodes of head, face, and neck |
| C84.A2 | Cutaneous t-cell lymphoma, unspecified, intrathoracic lymph nodes |
| C84.A3 | Cutaneous t-cell lymphoma, unspecified, intra-abdominal lymph nodes |
| C84.A4 | Cutaneous t-cell lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C84.A5 | Cutaneous t-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C84.A6 | Cutaneous t-cell lymphoma, unspecified, intrapelvic lymph nodes |
| C84.A7 | Cutaneous t-cell lymphoma, unspecified, spleen |
| C84.A8 | Cutaneous t-cell lymphoma, unspecified, lymph nodes of multiple sites |
| C84.A9 | Cutaneous t-cell lymphoma, unspecified, extranodal and solid organ sites |
| C84.Z | Other mature t/Nk-cell lymphomas |
| C84.Z0 | Other mature t/Nk-cell lymphomas, unspecified site |
| C84.Z1 | Other mature t/Nk-cell lymphomas, lymph nodes of head, face, and neck |
| C84.Z2 | Other mature t/Nk-cell lymphomas, intrathoracic lymph nodes |
| C84.Z3 | Other mature t/Nk-cell lymphomas, intra-abdominal lymph nodes |
| C84.Z4 | Other mature t/Nk-cell lymphomas, lymph nodes of axilla and upper limb |
| C84.Z5 | Other mature t/Nk-cell lymphomas, lymph nodes of inguinal region and lower limb |
| C84.Z6 | Other mature t/Nk-cell lymphomas, intrapelvic lymph nodes |
| C84.Z7 | Other mature t/Nk-cell lymphomas, spleen |
| C84.Z8 | Other mature t/Nk-cell lymphomas, lymph nodes of multiple sites |
| C84.Z9 | Other mature t/Nk-cell lymphomas, extranodal and solid organ sites |
| C85 | Other specified and unspecified types of non-hodgkin lymphoma |
| C85.1 | Unspecified b-cell lymphoma |
| C85.10 | Unspecified b-cell lymphoma, unspecified site |
| C85.11 | Unspecified b-cell lymphoma, lymph nodes of head, face, and neck |
| C85.12 | Unspecified b-cell lymphoma, intrathoracic lymph nodes |
| C85.13 | Unspecified b-cell lymphoma, intra-abdominal lymph nodes |
| C85.14 | Unspecified b-cell lymphoma, lymph nodes of axilla and upper limb |
| C85.15 | Unspecified b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C85.16 | Unspecified b-cell lymphoma, intrapelvic lymph nodes |
| C85.17 | Unspecified b-cell lymphoma, spleen |
| C85.18 | Unspecified b-cell lymphoma, lymph nodes of multiple sites |
| C85.19 | Unspecified b-cell lymphoma, extranodal and solid organ sites |
| C85.2 | Mediastinal (thymic) large b-cell lymphoma |
| C85.20 | Mediastinal (thymic) large b-cell lymphoma, unspecified site |
| C85.21 | Mediastinal (thymic) large b-cell lymphoma, lymph nodes of head, face, and neck |
| C85.22 | Mediastinal (thymic) large b-cell lymphoma, intrathoracic lymph nodes |
| C85.23 | Mediastinal (thymic) large b-cell lymphoma, intra-abdominal lymph nodes |
| C85.24 | Mediastinal (thymic) large b-cell lymphoma, lymph nodes of axilla and upper limb |
| C85.25 | Mediastinal (thymic) large b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C85.26 | Mediastinal (thymic) large b-cell lymphoma, intrapelvic lymph nodes |
| C85.27 | Mediastinal (thymic) large b-cell lymphoma, spleen |
| C85.28 | Mediastinal (thymic) large b-cell lymphoma, lymph nodes of multiple sites |
| C85.29 | Mediastinal (thymic) large b-cell lymphoma, extranodal and solid organ sites |
| C85.8 | Other specified types of non-hodgkin lymphoma |
| C85.80 | Other specified types of non-hodgkin lymphoma, unspecified site |
| C85.81 | Other specified types of non-hodgkin lymphoma, lymph nodes of head, face, and neck |
| C85.82 | Other specified types of non-hodgkin lymphoma, intrathoracic lymph nodes |
| C85.83 | Other specified types of non-hodgkin lymphoma, intra-abdominal lymph nodes |
| C85.84 | Other specified types of non-hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C85.85 | Other specified types of non-hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C85.86 | Other specified types of non-hodgkin lymphoma, intrapelvic lymph nodes |
| C85.87 | Other specified types of non-hodgkin lymphoma, spleen |
| C85.88 | Other specified types of non-hodgkin lymphoma, lymph nodes of multiple sites |
| C85.89 | Other specified types of non-hodgkin lymphoma, extranodal and solid organ sites |
| C85.9 | Non-hodgkin lymphoma, unspecified |
| C85.90 | Non-hodgkin lymphoma, unspecified, unspecified site |
| C85.91 | Non-hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck |
| C85.92 | Non-hodgkin lymphoma, unspecified, intrathoracic lymph nodes |
| C85.93 | Non-hodgkin lymphoma, unspecified, intra-abdominal lymph nodes |
| C85.94 | Non-hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C85.95 | Non-hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C85.96 | Non-hodgkin lymphoma, unspecified, intrapelvic lymph nodes |
| C85.97 | Non-hodgkin lymphoma, unspecified, spleen |
| C85.98 | Non-hodgkin lymphoma, unspecified, lymph nodes of multiple sites |
| C85.99 | Non-hodgkin lymphoma, unspecified, extranodal and solid organ sites |
| C86 | Other specified types of t/Nk-cell lymphoma |
| C86.0 | Extranodal Nk/t-cell lymphoma, nasal type |
| C86.1 | Hepatosplenic t-cell lymphoma |
| C86.2 | Enteropathy-type (intestinal) t-cell lymphoma |
| C86.3 | Subcutaneous panniculitis-like t-cell lymphoma |
| C86.4 | Blastic Nk-cell lymphoma |
| C86.5 | Angioimmunoblastic t-cell lymphoma |
| C86.6 | Primary cutaneous Cd30-positive t-cell proliferations |
| C88 | Malignant immunoproliferative diseases and certain other b-cell lymphomas |
| C88.0 | Waldenstrom macroglobulinemia |
| C88.3 | Immunoproliferative small intestinal disease |
| C88.4 | Extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue [MALt-lymphoma] |
| C88.8 | Other malignant immunoproliferative diseases |
| C88.9 | Malignant immunoproliferative disease, unspecified |
| C90 | Multiple myeloma and malignant plasma cell neoplasms |
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| C90.1 | Plasma cell leukemia |
| C90.10 | Plasma cell leukemia not having achieved remission |
| C90.12 | Plasma cell leukemia in relapse |
| C90.2 | Extramedullary plasmacytoma |
| C90.20 | Extramedullary plasmacytoma not having achieved remission |
| C90.22 | Extramedullary plasmacytoma in relapse |
| C90.3 | Solitary plasmacytoma |
| C90.30 | Solitary plasmacytoma not having achieved remission |
| C90.32 | Solitary plasmacytoma in relapse |
| C91 | Lymphoid leukemia |
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| C91.3 | Prolymphocytic leukemia of b-cell type |
| C91.30 | Prolymphocytic leukemia of b-cell type not having achieved remission |
| C91.32 | Prolymphocytic leukemia of b-cell type, in relapse |
| C91.4 | Hairy cell leukemia |
| C91.40 | Hairy cell leukemia not having achieved remission |
| C91.42 | Hairy cell leukemia, in relapse |
| C91.5 | Adult t-cell lymphoma/leukemia (HTLv-1-associated) |
| C91.50 | Adult t-cell lymphoma/leukemia (HTLv-1-associated) not having achieved remission |
| C91.52 | Adult t-cell lymphoma/leukemia (HTLv-1-associated), in relapse |
| C91.6 | Prolymphocytic leukemia of t-cell type |
| C91.60 | Prolymphocytic leukemia of t-cell type not having achieved remission |
| C91.62 | Prolymphocytic leukemia of t-cell type, in relapse |
| C91.9 | Lymphoid leukemia, unspecified |
| C91.90 | Lymphoid leukemia, unspecified not having achieved remission |
| C91.92 | Lymphoid leukemia, unspecified, in relapse |
| C91.A | Mature b-cell leukemia burkitt-type |
| C91.A0 | Mature b-cell leukemia burkitt-type not having achieved remission |
| C91.A2 | Mature b-cell leukemia burkitt-type, in relapse |
| C91.Z | Other lymphoid leukemia |
| C91.Z0 | Other lymphoid leukemia not having achieved remission |
| C91.Z2 | Other lymphoid leukemia, in relapse |
| C92 | Myeloid leukemia |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.1 | Chronic myeloid leukemia, BCr/ABl-positive |
| C92.10 | Chronic myeloid leukemia, BCr/ABl-positive, not having achieved remission |
| C92.12 | Chronic myeloid leukemia, BCr/ABl-positive, in relapse |
| C92.2 | Atypical chronic myeloid leukemia, BCr/ABl-negative |
| C92.20 | Atypical chronic myeloid leukemia, BCr/ABl-negative, not having achieved remission |
| C92.22 | Atypical chronic myeloid leukemia, BCr/ABl-negative, in relapse |
| C92.3 | Myeloid sarcoma |
| C92.30 | Myeloid sarcoma, not having achieved remission |
| C92.32 | Myeloid sarcoma, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C92.9 | Myeloid leukemia, unspecified |
| C92.90 | Myeloid leukemia, unspecified, not having achieved remission |
| C92.92 | Myeloid leukemia, unspecified in relapse |
| C92.A | Acute myeloid leukemia with multilineage dysplasia |
| C92.A0 | Acute myeloid leukemia with multilineage dysplasia, not having achieved remission |
| C92.A2 | Acute myeloid leukemia with multilineage dysplasia, in relapse |
| C92.Z | Other myeloid leukemia |
| C92.Z0 | Other myeloid leukemia not having achieved remission |
| C92.Z2 | Other myeloid leukemia, in relapse |
| C93 | Monocytic leukemia |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C93.1 | Chronic myelomonocytic leukemia |
| C93.10 | Chronic myelomonocytic leukemia not having achieved remission |
| C93.12 | Chronic myelomonocytic leukemia, in relapse |
| C93.3 | Juvenile myelomonocytic leukemia |
| C93.30 | Juvenile myelomonocytic leukemia, not having achieved remission |
| C93.32 | Juvenile myelomonocytic leukemia, in relapse |
| C93.9 | Monocytic leukemia, unspecified |
| C93.90 | Monocytic leukemia, unspecified, not having achieved remission |
| C93.92 | Monocytic leukemia, unspecified in relapse |
| C93.Z | Other monocytic leukemia |
| C93.Z0 | Other monocytic leukemia, not having achieved remission |
| C93.Z2 | Other monocytic leukemia, in relapse |
| C94 | Other leukemias of specified cell type |
| C94.0 | Acute erythroid leukemia |
| C94.00 | Acute erythroid leukemia, not having achieved remission |
| C94.02 | Acute erythroid leukemia, in relapse |
| C94.2 | Acute megakaryoblastic leukemia |
| C94.20 | Acute megakaryoblastic leukemia not having achieved remission |
| C94.22 | Acute megakaryoblastic leukemia, in relapse |
| C94.3 | Mast cell leukemia |
| C94.30 | Mast cell leukemia not having achieved remission |
| C94.32 | Mast cell leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
| C94.6 | Myelodysplastic disease, not elsewhere classified |
| C94.8 | Other specified leukemias |
| C94.80 | Other specified leukemias not having achieved remission |
| C94.82 | Other specified leukemias, in relapse |
| C95 | Leukemia of unspecified cell type |
| C95.0 | Acute leukemia of unspecified cell type |
| C95.00 | Acute leukemia of unspecified cell type not having achieved remission |
| C95.02 | Acute leukemia of unspecified cell type, in relapse |
| C95.1 | Chronic leukemia of unspecified cell type |
| C95.10 | Chronic leukemia of unspecified cell type not having achieved remission |
| C95.12 | Chronic leukemia of unspecified cell type, in relapse |
| C95.9 | Leukemia, unspecified |
| C95.90 | Leukemia, unspecified not having achieved remission |
| C95.92 | Leukemia, unspecified, in relapse |
| C96 | Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue |
| C96.0 | Multifocal and multisystemic (disseminated) langerhans-cell histiocytosis |
| C96.2 | Malignant mast cell neoplasm |
| C96.20 | Malignant mast cell neoplasm, unspecified |
| C96.21 | Aggressive systemic mastocytosis |
| C96.22 | Mast cell sarcoma |
| C96.29 | Other malignant mast cell neoplasm |
| C96.4 | Sarcoma of dendritic cells (accessory cells) |
| C96.5 | Multifocal and unisystemic langerhans-cell histiocytosis |
| C96.6 | Unifocal langerhans-cell histiocytosis |
| C96.9 | Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified |
| C96.A | Histiocytic sarcoma |
| C96.Z | Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| Severe chronic neutropenia | |
| D70.8 | Other neutropenia |
| D70.9 | Neutropenia, unspecified |
Formulary Reference Tool